HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

CEAs

If you want to keep on top of the latest CEAs, below are our quick monthly searches of journals.  Please note this isn't meant to be comprehensive....if you want that, or any other searches, please contact us!

July 2017

1.    Bansback N, Phibbs CS, Sun H, O'Dell JR, Brophy M, Keystone EC, et al. Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. Annals of internal medicine. 2017;167(1):8-16.
2.    Borrelli J, Jr. Invited Commentary: Cost-Utility Analysis of Reconstruction Versus Primary Amputation for Type IIIB and Type C Open Tibia Fractures. Journal of orthopaedic trauma. 2017.
3.    Borse MS, Dong OM, Polasek MJ, Farley JF, Stouffer GA, Lee CR. CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. Pharmacogenomics. 2017;18(12):1155-66.
4.    Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren's Syndrome. Arthritis & rheumatology (Hoboken, NJ). 2017;69(7):1440-50.
5.    Buchanan J, Wordsworth S, Clifford R, Robbe P, Taylor JC, Schuh A, et al. Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis. PharmacoEconomics. 2017.
6.    Burgers LT, Redekop WK, Al MJ, Lhachimi SK, Armstrong N, Walker S, et al. Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients. The European journal of health economics : HEPAC : health economics in prevention and care. 2017;18(6):731-42.
7.    Cazarim MS, da Cruz-Cazarim ELC, Baldoni AO, Dos Santos TBE, de Souza PG, Silva IA, et al. Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus. Diabetes & metabolic syndrome. 2017.
8.    Chouaid C, Luciani L, LeLay K, Do P, Bennouna J, Perol M, et al. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for first line treatment of advanced EGFR-Mutated Advanced Non-Small-Cell Lung Cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017.
9.    Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, et al. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis. Liver international : official journal of the International Association for the Study of the Liver. 2017;37(7):982-94.
10.    Clarke M, Fursse J, Connolly N, Sharma U, Jones R. Evaluation of the National Health Service (NHS) Direct Pilot Telehealth Program: Cost-Effectiveness Analysis. Telemedicine journal and e-health : the official journal of the American Telemedicine Association. 2017.
11.    Ding H, Fang L, Xin W, Tong Y, Zhou Q, Huang P. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer. European journal of cancer care. 2017.
12.    Dobie RA. In reference to To image or not to Image? A cost-effectiveness analysis of MRI for patients with asymmetric sensorineural hearing loss. The Laryngoscope. 2017.
13.    Escribano Ferrer B, Hansen KS, Gyapong M, Bruce J, Narh Bana SA, Narh CT, et al. Cost-effectiveness analysis of the national implementation of integrated community case management and community-based health planning and services in Ghana for the treatment of malaria, diarrhoea and pneumonia. Malaria journal. 2017;16(1):277.
14.    Goto D, Shih YT, Lecomte P, Olson M, Udeze C, Park Y, et al. Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis. PharmacoEconomics. 2017;35(7):685-95.
15.    Gunda R, Chimbari MJ. Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review. Cost effectiveness and resource allocation : C/E. 2017;15:10.
16.    Jiang M, You JHS. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome. Clinical cardiology. 2017.
17.    Kolesar RJ, Audibert M, Comfort AB. Cost-effectiveness analysis and mortality impact estimation of scaling-up pregnancy test kits in Madagascar, Ethiopia and Malawi. Health policy and planning. 2017;32(6):869-81.
18.    Kortz TB, Herzel B, Marseille E, Kahn JG. Bubble continuous positive airway pressure in the treatment of severe paediatric pneumonia in Malawi: a cost-effectiveness analysis. BMJ open. 2017;7(7):e015344.
19.    Lamsal R, Stalker CA, Cait CA, Riemer M, Horton S. Cost-effectiveness analysis of single-session walk-in counselling. Journal of mental health (Abingdon, England). 2017:1-7.
20.    Long LC, Maskew M, Brennan AT, Mongwenyana C, Nyoni C, Malete G, et al. Initiating antiretroviral therapy for HIV at a patient's first clinic visit: a cost-effectiveness analysis of the rapid initiation of treatment randomized controlled trial. AIDS (London, England). 2017;31(11):1611-9.
21.    Mennini FS, Bonanni P, Bianic F, de Waure C, Baio G, Plazzotta G, et al. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. Cost effectiveness and resource allocation : C/E. 2017;15:11.
22.    Mezquita-Raya P, Darba J, Ascanio M, Ramirez de Arellano A. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective. Expert review of pharmacoeconomics & outcomes research. 2017:1-9.
23.    Mo X, Gai Tobe R, Wang L, Liu X, Wu B, Luo H, et al. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. BMC infectious diseases. 2017;17(1):502.
24.    Moretti ME, Lato DF, Berger H, Koren G, Ito S, Ungar WJ. A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events. The pharmacogenomics journal. 2017.
25.    Mukerji S, MacIntyre CR, Seale H, Wang Q, Yang P, Wang X, et al. Cost-effectiveness analysis of N95 respirators and medical masks to protect healthcare workers in China from respiratory infections. BMC infectious diseases. 2017;17(1):464.
26.    Neoh CF, Senol E, Kara A, Dinleyici EC, Turner SJ, Kong DCM. Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey. Mycoses. 2017.
27.    Offodile AC, 2nd, Sheckter CC, Tucker A, Watzker A, Ottino K, Zammert M, et al. Preoperative paravertebral blocks for the management of acute pain following mastectomy: a cost-effectiveness analysis. Breast cancer research and treatment. 2017.
28.    Pershad J, Taylor A, Hall MK, Klimo P, Jr. Imaging Strategies for Suspected Acute Cranial Shunt Failure: A Cost-Effectiveness Analysis. Pediatrics. 2017;140(2).
29.    Pinsky MR, Valentin A, Rubenfeld G. Intensive Care Medicine in 2050: cost-effectiveness analysis. Intensive care medicine. 2017;43(7):1039-40.
30.    Sadler S, Tosh J, Pennington R, Rawdin A, Squires H, Romero C, et al. A cost-effectiveness analysis of condom distribution programmes for the prevention of sexually transmitted infections in England. Journal of epidemiology and community health. 2017.
31.    Shi CR, Nambudiri VE. Research Techniques Made Simple: Cost-Effectiveness Analysis. The Journal of investigative dermatology. 2017;137(7):e143-e7.
32.    Suh CH, Kim KW, Park SH, Shin S, Ahn J, Pyo J, et al. A cost-effectiveness analysis of the diagnostic strategies for differentiating focal nodular hyperplasia from hepatocellular adenoma. European radiology. 2017.
33.    Timmermans MJC, van den Brink GT, van Vught A, Adang E, van Berlo CLH, Boxtel KV, et al. The involvement of physician assistants in inpatient care in hospitals in the Netherlands: a cost-effectiveness analysis. BMJ open. 2017;7(7):e016405.
34.    Toohill J, Callander E, Gamble J, Creedy DK, Fenwick J. A cost effectiveness analysis of midwife psycho-education for fearful pregnant women - a health system perspective for the antenatal period. BMC pregnancy and childbirth. 2017;17(1):217.
35.    van Kampen RJW, Ramaekers BLT, Lobbezoo DJA, de Boer M, Dercksen MW, van den Berkmortel F, et al. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. European journal of cancer (Oxford, England : 1990). 2017;79:238-46.
36.    Wali AR, Santiago-Dieppa DR, Brown JM, Mandeville R. Nerve transfer versus muscle transfer to restore elbow flexion after pan-brachial plexus injury: a cost-effectiveness analysis. Neurosurgical focus. 2017;43(1):E4.
37.    Watt M, Dinh A, Le Monnier A, Tilleul P. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. Journal of medical economics. 2017;20(7):678-86.
38.    Yang H, Duchesneau E, Foster R, Guerin A, Ma E, Thomas NP. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. Journal of medical economics. 2017:1-10.
39.    Zhang P, Wen F, Fu P, Yang Y, Li Q. Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis. Tumori. 2017;103(4):380-6.
40.    Zheng J, Zhang H, Chen H. Group B Streptococci Screening Before Repeat Cesarean Delivery: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2017;130(1):217.


June 2017

1.            Antillon M, Bilcke J, Paltiel AD, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine. 2017;35(27):3506-14.
2.            April MD, Murray BP. Cost-effectiveness Analysis Appraisal and Application: An Emergency Medicine Perspective. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2017;24(6):754-68.
3.            Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren's Syndrome. Arthritis & rheumatology (Hoboken, NJ). 2017;69(7):1440-50.
4.            Clement RC, Lang PJ, Pettett BJ, Overman RA, Ostrum RF, Tennant JN. Sanders II/III Calcaneus Fractures in Laborers: A Cost-Effectiveness Analysis and Call for Effectiveness Research. Journal of orthopaedic trauma. 2017;31(6):299-304.
5.            Cortesi PA, D'Angiolella LS, Vellucci R, Allegri M, Casale G, Favaretti C, et al. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment. PloS one. 2017;12(6):e0179523.
6.            Cotton CC, Erim D, Eluri S, Palmer SH, Green DJ, Wolf WA, et al. Cost Utility Analysis of Topical Steroids Compared With Dietary Elimination for Treatment of Eosinophilic Esophagitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2017;15(6):841-9.e1.
7.            Crowson MG, Rocke DJ, Hoang JK, Weissman JL, Kaylie DM. Cost-effectiveness analysis of a non-contrast screening MRI protocol for vestibular schwannoma in patients with asymmetric sensorineural hearing loss. Neuroradiology. 2017.
8.            Cutti AG, Lettieri E, Del Maestro M, Radaelli G, Luchetti M, Verni G, et al. Stratified cost-utility analysis of C-Leg versus mechanical knees: Findings from an Italian sample of transfemoral amputees. Prosthetics and orthotics international. 2017;41(3):227-36.
9.            Elhennawy K, Jost-Brinkmann PG, Manton DJ, Paris S, Schwendicke F. Managing molars with severe molar-incisor hypomineralization: A cost-effectiveness analysis within German healthcare. Journal of dentistry. 2017.
10.          Evers PD, Ranade D, Lewin M, Arya B. Diagnostic Approach in Fetal Coarctation of the Aorta: A Cost-Utility Analysis. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2017;30(6):589-94.
11.          Goldstein DA, Chen Q, Ayer T, Chan KKW, Virik K, Hammerman A, et al. Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. The oncologist. 2017;22(6):694-9.
12.          Gourzoulidis G, Kourlaba G, Kakisis J, Matsagkas M, Giannakoulas G, Gourgoulianis KI, et al. Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece. Clinical drug investigation. 2017.
13.          Hall RK, Myers ER, Rosas SE, O'Hare AM, Colon-Emeric CS. Choice of Hemodialysis Access in Older Adults: A Cost-Effectiveness Analysis. Clinical journal of the American Society of Nephrology : CJASN. 2017;12(6):947-54.
14.          Hansen KS, Ndyomugyenyi R, Magnussen P, Lal S, Clarke SE. Cost-effectiveness analysis of malaria rapid diagnostic tests for appropriate treatment of malaria at the community level in Uganda. Health policy and planning. 2017;32(5):676-89.
15.          Heisen M, Treur MJ, Heemstra HE, Giesen EBW, Postma MJ. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands. Journal of medical economics. 2017:1-12.
16.          Hernaes UJV, Johansson KA, Ottersen T, Norheim OF. Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss. PharmacoEconomics. 2017.
17.          Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, et al. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer. 2017.
18.          Hunt B, Mocarski M, Valentine WJ, Langer J. IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2017;8(3):531-44.
19.          Julicher P, Greenslade JH, Parsonage WA, Cullen L. The organisational value of diagnostic strategies using high-sensitivity troponin for patients with possible acute coronary syndromes: a trial-based cost-effectiveness analysis. BMJ open. 2017;7(6):e013653.
20.          Kameda M, Yamada S, Atsuchi M, Kimura T, Kazui H, Miyajima M, et al. Cost-effectiveness analysis of shunt surgery for idiopathic normal pressure hydrocephalus based on the SINPHONI and SINPHONI-2 trials. Acta neurochirurgica. 2017;159(6):995-1003.
21.          Ke CH, Chung WH, Wen YH, Huang YB, Chuang HY, Tain YL, et al. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions. The Journal of rheumatology. 2017;44(6):835-43.
22.          Krog AH, Sahba M, Pettersen EM, Wisloff T, Sundhagen JO, Kazmi SS. Cost-utility analysis comparing laparoscopic vs open aortobifemoral bypass surgery. Vascular health and risk management. 2017;13:217-24.
23.          Lapointe-Shaw L, Voruganti T, Kohler P, Thein HH, Sander B, McGeer A. Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2017;36(6):1047-55.
24.          Lucchese M, Borisenko O, Mantovani LG, Cortesi PA, Cesana G, Adam D, et al. Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling. Obesity facts. 2017;10(3):261-72.
25.          McGuffin M, Merino T, Keller B, Pignol JP. Response to: 'Reply to: Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer'. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017;29(6):393-4.
26.          Mercier G, Loureiro M, Georgescu V, Skalli EM, Nedelcu M, Ramadan M, et al. Surgical glue in laparoscopic sleeve gastrectomy: An initial experience and cost-effectiveness analysis. Journal of evaluation in clinical practice. 2017;23(3):614-9.
27.          Mezquita-Raya P, Darba J, Ascanio M, Ramirez de Arellano A. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective. Expert review of pharmacoeconomics & outcomes research. 2017:1-9.
28.          Michael J, Crook J, Morton D, Batchelar D, Hilts M, Fenster A. Reply to: Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017;29(6):392-3.
29.          Moriwaki K, Mouri M, Hagino H. Erratum to: Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2017;28(6):1951-2.
30.          Moriwaki K, Mouri M, Hagino H. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2017;28(6):1939-50.
31.          Rivera F, Valladares M, Gea S, Lopez-Martinez N. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Journal of medical economics. 2017;20(6):574-84.
32.          Ruiz-Ramos J, Frasquet J, Roma E, Poveda-Andres JL, Salavert-Leti M, Castellanos A, et al. Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units. Journal of medical economics. 2017;20(6):652-9.
33.          Sanchez Fernandez I, Gainza-Lein M, Loddenkemper T. Nonintravenous rescue medications for pediatric status epilepticus: A cost-effectiveness analysis. Epilepsia. 2017.
34.          Shaikh N, Dando EE, Dunleavy ML, Curran DL, Martin JM, Hoberman A, et al. A Cost-Utility Analysis of 5 Strategies for the Management of Acute Otitis Media in Children. The Journal of pediatrics. 2017.
35.          Shechter SM, Chandler T, Skandari MR, Zalunardo N. Cost-effectiveness Analysis of Vascular Access Referral Policies in CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2017.
36.          Shillcutt SD, LeFevre AE, Fischer-Walker CL, Taneja S, Black RE, Mazumder S. Cost-effectiveness analysis of the diarrhea alleviation through zinc and oral rehydration therapy (DAZT) program in rural Gujarat India: an application of the net-benefit regression framework. Cost effectiveness and resource allocation : C/E. 2017;15:9.
37.          Tamoschus D, Draexler K, Chang J, Ngai C, Madin-Warburton M, Pitcher A. Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany. Clinical drug investigation. 2017;37(6):525-33.
38.          Thomas KH, Caldwell D, Dalili MN, Gunnell D, Munafo MR, Stevenson M, et al. How do smoking cessation medicines compare with respect to their neuropsychiatric safety? A protocol for a systematic review, network meta-analysis and cost-effectiveness analysis. BMJ open. 2017;7(6):e015414.
39.          Trenaman L, Stacey D, Bryan S, Taljaard M, Hawker G, Dervin G, et al. Patient decision aids for patients considering total joint replacement: a cost-effectiveness analysis alongside a randomised controlled trial (RCT). Osteoarthritis and cartilage. 2017.
40.          Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, et al. Corrigendum to "Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy" [Eur J Cancer 67 (2016) 38-45]. European journal of cancer (Oxford, England : 1990). 2017.
41.          Turnes J, Dominguez-Hernandez R, Casado MA. Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. Gastroenterologia y hepatologia. 2017.
42.          Wali AR, Park CC, Santiago-Dieppa DR, Vaida F, Murphy JD, Khalessi AA. Pipeline embolization device versus coiling for the treatment of large and giant unruptured intracranial aneurysms: a cost-effectiveness analysis. Neurosurgical focus. 2017;42(6):E6.
43.          Wikman-Jorgensen PE, Llenas-Garcia J, Perez-Porcuna TM, Hobbins M, Ehmer J, Mussa MA, et al. Microscopic observation drug-susceptibility assay vs. Xpert(R) MTB/RIF for the diagnosis of tuberculosis in a rural African setting: a cost-utility analysis. Tropical medicine & international health : TM & IH. 2017;22(6):734-43.
44.          Wu B, Yang Z, Tobe RG, Wang Y. Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2017.
45.          Xu B, Wang Q, Jin H, Li JX, Liu HN, Mao YJ, et al. [Internal fixation and hemiarthroplasty for the treatment of displaced femoral neck fracture: a cost-utility analysis]. Zhonghua yi xue za zhi. 2017;97(21):1650-4.
46.          Zhang S, Incardona B, Qazi SA, Stenberg K, Campbell H, Nair H. Cost-effectiveness analysis of revised WHO guidelines for management of childhood pneumonia in 74 Countdown countries. Journal of global health. 2017;7(1):010409.


May 2017

1.    Erratum to "The impact of nutrition support on clinical outcome and cost-effectiveness analysis in patients at nutritional risk: a prospective cohort study with propensity score matching," Nutrition (2017) 37C, 53-59. Nutrition (Burbank, Los Angeles County, Calif). 2017.
2.    Expression of Concern: Adaptive Pacing, Cognitive Behaviour Therapy, Graded Exercise, and Specialist Medical Care for Chronic Fatigue Syndrome: A Cost-Effectiveness Analysis. PloS one. 2017;12(5):e0177037.
3.    Antillon M, Bilcke J, Paltiel AD, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine. 2017;35(27):3506-14.
4.    April MD, Murray BP. Cost-effectiveness Analysis Appraisal and Application: An Emergency Medicine Perspective. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2017;24(6):754-68.
5.    Bansback N, Phibbs CS, Sun H, O'Dell JR, Brophy M, Keystone EC, et al. Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. Annals of internal medicine. 2017.
6.    Bojke L, Manca A, Asaria M, Mahon R, Ren S, Palmer S. How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis. PharmacoEconomics. 2017.
7.    Breeze PR, Thomas C, Squires H, Brennan A, Greaves C, Diggle PJ, et al. The impact of Type 2 diabetes prevention programmes based on risk-identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis. Diabetic medicine : a journal of the British Diabetic Association. 2017;34(5):632-40.
8.    Cardona-Arias JA, Lopez-Carvajal L, Tamayo Plata MP, Velez ID. Cost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis. Journal of evidence-based medicine. 2017;10(2):81-90.
9.    Ceballos M, Valderrama CO, Orozco LE, Sanchez L, Valderrama JP, Lugo LH. Cost-utility analysis of reconstruction compared with primary amputation for patients with severe lower limb trauma in Colombia. Journal of orthopaedic trauma. 2017.
10.    Coppola A, D'Ausilio A, Aiello A, Amoresano S, Toumi M, Mathew P, et al. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. Haemophilia : the official journal of the World Federation of Hemophilia. 2017;23(3):422-9.
11.    Davis SA, Himmler S, Feldman SR. Cost-effectiveness analysis of using dermatologists versus pediatricians to treat mild to moderate acne. Dermatology online journal. 2017;23(5).
12.    De Groot S, Blommestein HM, Redekop WK, Sleijfer S, Kiemeney L, Oosterwijk E, et al. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. PloS one. 2017;12(5):e0177364.
13.    Devine A, Parmiter M, Chu CS, Bancone G, Nosten F, Price RN, et al. Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis. PLoS neglected tropical diseases. 2017;11(5):e0005602.
14.    El-Saiedi SA, El Sisi AM, Mandour RS, Abdel-Aziz DM, Attia WA. Cost-effectiveness analysis of different devices used for the closure of small-to-medium-sized patent ductus arteriosus in pediatric patients. Annals of pediatric cardiology. 2017;10(2):144-51.
15.    Filby A, Taylor M, Lipman G, Lovat L, Haidry R. Cost-effectiveness analysis of endoscopic eradication therapy for treatment of high-grade dysplasia in Barrett's esophagus. Journal of comparative effectiveness research. 2017.
16.    Germar MJ, Purugganan C, Bernardino MS, Cuenca B, Chen YC, Li X, et al. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule. Human vaccines & immunotherapeutics. 2017;13(5):1158-66.
17.    Godefrooij DA, Mangen MJ, Chan E, O'Brart DPS, Imhof SM, de Wit GA, et al. Cost-Effectiveness Analysis of Corneal Collagen Crosslinking for Progressive Keratoconus. Ophthalmology. 2017.
18.    Gordon LG, James R, Tuffaha HW, Lowe A, Yaxley J. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia. Journal of magnetic resonance imaging : JMRI. 2017;45(5):1304-15.
19.    Grover R, Rueda S, Gurunluoglu R. Is Single-Stage Prosthetic Reconstruction Cost Effective? A Cost-Utility Analysis for the Use of Direct-to-Implant Breast Reconstruction Relative to Expander-Implant Reconstruction in Postmastectomy Patients. Plastic and reconstructive surgery. 2017;139(5):1204e-5e.
20.    Hall RK, Myers ER, Rosas SE, O'Hare AM, Colon-Emeric CS. Choice of Hemodialysis Access in Older Adults: A Cost-Effectiveness Analysis. Clinical journal of the American Society of Nephrology : CJASN. 2017;12(6):947-54.
21.    Hansen TB, Zwisler AD, Berg SK, Sibilitz KL, Thygesen LC, Kjellberg J, et al. Cost-utility analysis of cardiac rehabilitation after conventional heart valve surgery versus usual care. European journal of preventive cardiology. 2017;24(7):698-707.
22.    Haukaas FS, Arnesen TM, Winje BA, Aas E. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis. The European journal of health economics : HEPAC : health economics in prevention and care. 2017;18(4):405-15.
23.    Heisen M, Treur MJ, Heemstra HE, Giesen EBW, Postma MJ. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands. Journal of medical economics. 2017:1-27.
24.    Johri M, Ng ESW, Bermudez-Tamayo C, Hoch JS, Ducruet T, Chaillet N. A cluster-randomized trial to reduce caesarean delivery rates in Quebec: cost-effectiveness analysis. BMC medicine. 2017;15(1):96.
25.    Kim H, Rajagopalan MS, Beriwal S, Smith KJ. Cost-effectiveness Analysis of Stereotactic Radiosurgery Alone Versus Stereotactic Radiosurgery with Upfront Whole Brain Radiation Therapy for Brain Metastases. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017.
26.    Krishnan NM, Fischer JP, Basta MN, Nahabedian MY. Reply: Is Single-Stage Prosthetic Reconstruction Cost Effective? A Cost-Utility Analysis for the Use of Direct-to-Implant Breast Reconstruction Relative to Expander-Implant Reconstruction in Postmastectomy Patients. Plastic and reconstructive surgery. 2017;139(5):1205e-6e.
27.    Long LC, Maskew M, Brennan AT, Mongwenyana C, Nyoni C, Malete G, et al. Initiating antiretroviral therapy for HIV at a patient's first clinic visit: A cost-effectiveness analysis of the RapIT randomized controlled trial. AIDS (London, England). 2017.
28.    Manchikanti L, Pampati V, Benyamin RM, Hirsch JA. Cost Utility Analysis of Lumbar Interlaminar Epidural Injections in the Treatment of Lumbar Disc Herniation, Central Spinal Stenosis, and Axial or Discogenic Low Back Pain. Pain physician. 2017;20(4):219-28.
29.    Mullie GA, Schwartzman K, Zwerling A, N'Diaye DS. Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis. BMC medicine. 2017;15(1):104.
30.    Pepe A, Rossi G, Bentley A, Putti MC, Frizziero L, D'Ascola DG, et al. Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in beta-Thalassaemia Major Patients: An Italian Perspective. Clinical drug investigation. 2017;37(5):453-64.
31.    Schrock JB, Kraeutler MJ, Houck DA, McQueen MB, McCarty EC. A Cost-Effectiveness Analysis of Surgical Treatment Modalities for Chondral Lesions of the Knee: Microfracture, Osteochondral Autograft Transplantation, and Autologous Chondrocyte Implantation. Orthopaedic journal of sports medicine. 2017;5(5):2325967117704634.
32.    Silverstein A, Costas-Chavarri A, Gakwaya MR, Lule J, Mukhopadhyay S, Meara JG, et al. Laparoscopic Versus Open Cholecystectomy: A Cost-Effectiveness Analysis at Rwanda Military Hospital. World journal of surgery. 2017;41(5):1225-33.
33.    Sjostrom M, Lindholm L, Samuelsson E. Mobile App for Treatment of Stress Urinary Incontinence: A Cost-Effectiveness Analysis. Journal of medical Internet research. 2017;19(5):e154.
34.    Tapper EB, Hughes MS, Buti M, Dufour JF, Flamm S, Firdoos S, et al. The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Transplantation. 2017;101(5):987-95.
35.    Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, et al. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece. Rheumatology international. 2017.
36.    van der Meulen MP, Kapidzic A, van Leerdam ME, van der Steen A, Kuipers EJ, Spaander MC, et al. Do men and women need to be screened differently with faecal immunochemical testing? A cost-effectiveness analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2017.
37.    Van Minh H, My NTT, Jit M. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study. BMC health services research. 2017;17(1):353.
38.    van Oers AM, Mutsaerts MAQ, Burggraaff JM, Kuchenbecker WKH, Perquin DAM, Koks CAM, et al. Cost-effectiveness analysis of lifestyle intervention in obese infertile women. Human reproduction (Oxford, England). 2017:1-9.
39.    Vinten A, Sample J, Ibiyemi A, Abdul-Salam Y, Stutter M. A tool for cost-effectiveness analysis of field scale sediment-bound phosphorus mitigation measures and application to analysis of spatial and temporal targeting in the Lunan Water catchment, Scotland. The Science of the total environment. 2017;586:631-41.
40.    Whittington MD, Atherly AJ, Curtis DJ, Lindrooth RC, Bradley CJ, Campbell JD. Recommendations for Methicillin-Resistant Staphylococcus aureus Prevention in Adult ICUs: A Cost-Effectiveness Analysis. Critical care medicine. 2017.
41.    Wikman-Jorgensen PE, Llenas-Garcia J, Perez-Porcuna TM, Hobbins M, Ehmer J, Mussa MA, et al. Microscopic observation drug-susceptibility assay vs. Xpert(R) MTB/RIF for the diagnosis of tuberculosis in a rural African setting: a cost-utility analysis. Tropical medicine & international health : TM & IH. 2017;22(6):734-43.
42.    Williams C, Lewsey JD, Briggs AH, Mackay DF. Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial. Medical decision making : an international journal of the Society for Medical Decision Making. 2017;37(4):340-52.
43.    Wong CKH, Liao Q, Guo VYW, Xin Y, Lam CLK. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review. Vaccine. 2017;35(24):3153-61.
44.    Wysham WZ, Schaffer EM, Coles T, Roque DR, Wheeler SB, Kim KH. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial. Gynecologic oncology. 2017;145(2):340-5.
45.    Zhang H, Wang Y, Jiang ZM, Kondrup J, Fang H, Andrews M, et al. Impact of nutrition support on clinical outcome and cost-effectiveness analysis in patients at nutritional risk: A prospective cohort study with propensity score matching. Nutrition (Burbank, Los Angeles County, Calif). 2017;37:53-9.


April 2017

1.    Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I, et al. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology (Baltimore, Md). 2017;65(4):1237-48.
2.    Ceballos M, Orozco LE, Valderrama CO, Londono DI, Lugo LH. Cost-Effectiveness Analysis of the Use of a Prophylactic Antibiotic for Patients Undergoing Lower Limb Amputation due to Diabetes or Vascular Illness in Colombia. Annals of vascular surgery. 2017;40:327-34.
3.    Coyle D, Ko YJ, Coyle K, Saluja R, Shah K, Lien K, et al. Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(4):586-92.
4.    Evers PD, Ranade D, Lewin M, Arya B. Diagnostic Approach in Fetal Coarctation of the Aorta: A Cost-Utility Analysis. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2017.
5.    Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, et al. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. PharmacoEconomics. 2017;35(4):425-38.
6.    Garrido G, Penades R, Barrios M, Aragay N, Ramos I, Valles V, et al. Computer-assisted cognitive remediation therapy in schizophrenia: Durability of the effects and cost-utility analysis. Psychiatry research. 2017;254:198-204.
7.    Gordon LG, Brynes J, Baade PD, Neale RE, Whiteman DC, Youl PH, et al. Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(4):593-601.
8.    Goto D, Shih YT, Lecomte P, Olson M, Udeze C, Park Y, et al. Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis. PharmacoEconomics. 2017.
9.    Green AL, Gregory R. Cost-utility analysis alongside the PD SURG trial. Movement disorders : official journal of the Movement Disorder Society. 2017;32(4):631-2.
10.    Heller S, White D, Lee E, Lawton J, Pollard D, Waugh N, et al. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. Health technology assessment (Winchester, England). 2017;21(20):1-278.
11.    Hojjat H, Svider PF, Davoodian P, Hong RS, Folbe AJ, Eloy JA, et al. To image or not to image? A cost-effectiveness analysis of MRI for patients with asymmetric sensorineural hearing loss. The Laryngoscope. 2017;127(4):939-44.
12.    Johansson KA, Strand KB, Fekadu A, Chisholm D. Health Gains and Financial Protection Provided by the Ethiopian Mental Health Strategy: an Extended Cost-Effectiveness Analysis. Health policy and planning. 2017;32(3):376-83.
13.    Ke CH, Chung WH, Wen YH, Huang YB, Chuang HY, Tain YL, et al. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions. The Journal of rheumatology. 2017.
14.    Kempfle JS, BuSaba NY, Dobrowski JM, Westover MB, Bianchi MT. A cost-effectiveness analysis of nasal surgery to increase continuous positive airway pressure adherence in sleep apnea patients with nasal obstruction. The Laryngoscope. 2017;127(4):977-83.
15.    Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. Hepatology (Baltimore, Md). 2017;65(4):1156-64.
16.    Kolesar RJ, Audibert M, Comfort AB. Cost-effectiveness analysis and mortality impact estimation of scaling-up pregnancy test kits in Madagascar, Ethiopia and Malawi. Health policy and planning. 2017.
17.    Leung VC, Pechlivanoglou P, Chew HF, Hatch W. Corneal Collagen Cross-Linking in the Management of Keratoconus in Canada: A Cost-Effectiveness Analysis. Ophthalmology. 2017.
18.    Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, et al. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data. Journal of medical economics. 2017;20(4):328-36.
19.    Mantravadi S. Cost-Effectiveness Analysis of Interventions to Reduce Risk of Aspiration in Elderly Cancer Survivors Residing in Skilled Nursing Facilities. Cancer control : journal of the Moffitt Cancer Center. 2017;24(2):187-92.
20.    Mason JM, Thomas KS, Ormerod AD, Craig FE, Mitchell E, Norrie J, et al. Ciclosporin compared to prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial. The British journal of dermatology. 2017.
21.    Mason SE, Kinross JM, Hendricks J, Arulampalam TH. Postoperative hypothermia and surgical site infection following peritoneal insufflation with warm, humidified carbon dioxide during laparoscopic colorectal surgery: a cohort study with cost-effectiveness analysis. Surgical endoscopy. 2017;31(4):1923-9.
22.    McGuffin M, Merino T, Keller B, Pignol JP. Response to: 'Reply to: Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer'. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017;29(6):393-4.
23.    Miller HJ, Neupane R, Fayezizadeh M, Majumder A, Marks JM. POEM is a cost-effective procedure: cost-utility analysis of endoscopic and surgical treatment options in the management of achalasia. Surgical endoscopy. 2017;31(4):1636-42.
24.    Miyano S, Syakantu G, Komada K, Endo H, Sugishita T. Cost-effectiveness analysis of the national decentralization policy of antiretroviral treatment programme in Zambia. Cost effectiveness and resource allocation : C/E. 2017;15:4.
25.    Muthukumar M, Desai K, Abogunrin S, Harrower T, Gabriel S, Dinet J. Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom. ClinicoEconomics and outcomes research : CEOR. 2017;9:211-29.
26.    Nherera LM, Trueman P, Karlakki SL. Cost-effectiveness analysis of single-use negative pressure wound therapy dressings (sNPWT) to reduce surgical site complications (SSC) in routine primary hip and knee replacements. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 2017.
27.    Othus M, Bansal A, Koepl L, Wagner S, Ramsey S. Accounting for Cured Patients in Cost-Effectiveness Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(4):705-9.
28.    Phisalprapa P, Supakankunti S, Charatcharoenwitthaya P, Apisarnthanarak P, Charoensak A, Washirasaksiri C, et al. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. Medicine. 2017;96(17):e6585.
29.    Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, et al. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. PharmacoEconomics. 2017;35(4):479-91.
30.    Ruiz-Ramos J, Frasquet J, Roma E, Poveda-Andres JL, Salavert-Leti M, Castellanos A, et al. Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units. Journal of medical economics. 2017:1-8.
31.    Seagle BL, Shahabi S. Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. Gynecologic oncology. 2017;145(1):9-14.
32.    Sheng G, Chen S, Dong C, Zhang R, Miao M, Wu D, et al. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis. Journal of medical economics. 2017;20(4):371-81.
33.    Silver RM, Einerson BD. Cost-effectiveness analysis and Obstetrics: The time has come. BJOG : an international journal of obstetrics and gynaecology. 2017.
34.    Spolverato G, Vitale A, Bagante F, Connolly R, Pawlik TM. Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis. Annals of surgery. 2017;265(4):792-9.
35.    Suarez-Llanos JP, Benitez-Brito N, Vallejo-Torres L, Delgado-Brito I, Rosat-Rodrigo A, Hernandez-Carballo C, et al. Clinical and cost-effectiveness analysis of early detection of patients at nutrition risk during their hospital stay through the new screening method CIPA: a study protocol. BMC health services research. 2017;17(1):292.
36.    Takura T, Tachibana K, Isshiki T, Sumitsuji S, Kuroda T, Mizote I, et al. Preliminary report on a cost-utility analysis of revascularization by percutaneous coronary intervention for ischemic heart disease. Cardiovascular intervention and therapeutics. 2017;32(2):127-36.
37.    Takura T, Yoshimatsu M, Sugimori H, Takizawa K, Furumatsu Y, Ikeda H, et al. Cost-Effectiveness Analysis of Percutaneous Vertebroplasty for Osteoporotic Compression Fractures. Clinical spine surgery. 2017;30(3):E205-e10.
38.    Ten Eikelder MLG, van Baaren GJ, Rengerink KO, Jozwiak M, de Leeuw JW, Kleiverda G, et al. Comparing induction of labour with oral misoprostol or Foley catheter at term: cost effectiveness analysis of a randomised controlled multi-centre non-inferiority trial. BJOG : an international journal of obstetrics and gynaecology. 2017.
39.    Wikman-Jorgensen PE, Llenas-Garcia J, Perez-Porcuna TM, Hobbins M, Ehmer J, Mussa MA, et al. Microscopic observation drug-susceptibility assay vs. Xpert(R) MTB/RIF for the diagnosis of tuberculosis in a rural African setting: a cost-utility analysis. Tropical medicine & international health : TM & IH. 2017.
40.    Wilkinson A, Anderson S, Wheeler SB. Screening for and Treating Postpartum Depression and Psychosis: A Cost-Effectiveness Analysis. Maternal and child health journal. 2017;21(4):903-14.
41.    Wu B, Yao Y, Zhang K, Ma X. RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources. Oncotarget. 2017.
42.    Zhang L, Hu P. Cost-effectiveness analysis of oral versus intravenous drip infusion of levofloxacin in the treatment of acute lower respiratory tract infection in Chinese elderly patients. Clinical interventions in aging. 2017;12:673-8.
43.    Zygourakis CC, Imber BS, Chen R, Han SJ, Blevins L, Molinaro A, et al. Cost-Effectiveness Analysis of Surgical versus Medical Treatment of Prolactinomas. Journal of neurological surgery Part B, Skull base. 2017;78(2):125-31.


March 2017

1.    Aitken E, Thomson P, Bainbridge L, Kasthuri R, Mohr B, Kingsmore D. A randomized controlled trial and cost-effectiveness analysis of early cannulation arteriovenous grafts versus tunneled central venous catheters in patients requiring urgent vascular access for hemodialysis. Journal of vascular surgery. 2017;65(3):766-74.
2.    April MD, Murray BP. Cost-effectiveness analysis appraisal and application: an emergency medicine perspective. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2017.
3.    Aronsson M, Svennberg E, Rosenqvist M, Engdahl J, Al-Khalili F, Friberg L, et al. Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2017.
4.    Bove AM, Clohisy J, DeWitt J, Di Stasi S, Enseki K, Harris-Hayes M, et al. Cost-effectiveness Analysis of Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Individuals With Hip Labral Tears: Letter to the Editor. The American journal of sports medicine. 2017;45(3):Np1-np2.
5.    Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. Randomized Controlled Trial of Rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's Syndrome. Arthritis & rheumatology (Hoboken, NJ). 2017.
6.    Buti M, Dominguez-Hernandez R, Oyaguez I, Casado MA, Esteban R. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. Journal of viral hepatitis. 2017.
7.    Cho JH, Jang HM, Jung HY, Choi JY, Park SH, Kim CD, et al. A Real-world Cost-effectiveness Analysis of Sevelamer Versus Calcium Acetate in Korean Dialysis Patients. Clinical therapeutics. 2017.
8.    Clarke CS, Hunter RM, Shemilt I, Serra-Sastre V. Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective. PloS one. 2017;12(3):e0172731.
9.    Estades-Rubio FJ, Reyes-Martin A, Morales-Marcos V, Garcia-Piriz M, Garcia-Vera JJ, Peran M, et al. Knee Viscosupplementation: Cost-Effectiveness Analysis between Stabilized Hyaluronic Acid in a Single Injection versus Five Injections of Standard Hyaluronic Acid. International journal of molecular sciences. 2017;18(3).
10.    Ferket BS, Feldman Z, Zhou J, Oei EH, Bierma-Zeinstra SM, Mazumdar M. Impact of total knee replacement practice: cost effectiveness analysis of data from the Osteoarthritis Initiative. BMJ (Clinical research ed). 2017;356:j1131.
11.    Garrison LP, Jr., Zimmermann MR, Young CH, Crittendon J, Genereux P. Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-up. Cardiovascular revascularization medicine : including molecular interventions. 2017;18(2):86-90.
12.    Hermans J, Reijman M, Goossens LM, Verburg H, Bierma-Zeinstra SM, Koopmanschap MA. A cost utility analysis of high molecular weight hyaluronic acid for knee osteoarthritis in everyday clinical care in patients in the working age. An economic evaluation of a randomized clinical trial. Arthritis care & research. 2017.
13.    Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq SF. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. Journal of medical economics. 2017;20(3):228-38.
14.    Hunt B, Mocarski M, Valentine WJ, Langer J. IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2017.
15.    Hwang HJ, Guidi MA, Curvale C, Lasa J, Matano R. Post-ERCP pancreatitis: early precut or pancreatic duct stent? A multicenter, randomized-controlled trial and cost-effectiveness analysis. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 2017;109(3):174-9.
16.    Kameda M, Yamada S, Atsuchi M, Kimura T, Kazui H, Miyajima M, et al. Cost-effectiveness analysis of shunt surgery for idiopathic normal pressure hydrocephalus based on the SINPHONI and SINPHONI-2 trials. Acta neurochirurgica. 2017.
17.    Lee TH, Kim W, Shin J, Park EC, Park S, Kim TH. Strategic Distributional Cost-Effectiveness Analysis for Improving National Cancer Screening Uptake in Cervical Cancer: A Focus on Regional Inequality in South Korea. Cancer research and treatment : official journal of Korean Cancer Association. 2017.
18.    Liow MH, Agrawal K, Anderson DW, Freiberg AA, Rubash HE, Kwon YM. Unsuspected Malignancies in Routine Femoral Head Histopathologic Examination During Primary Total Hip Arthroplasty: Cost-Effectiveness Analysis. The Journal of arthroplasty. 2017;32(3):735-42.
19.    Liu CY, Chen HC. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan. Clinical drug investigation. 2017;37(3):285-93.
20.    Lodhia P, Gui C, Chandrasekaran S, Suarez-Ahedo C, Dirschl DR, Domb BG. Cost-effectiveness Analysis of Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Individuals With Hip Labral Tears: Response. The American journal of sports medicine. 2017;45(3):Np2-np4.
21.    May AM, Bosch MJ, Velthuis MJ, van der Wall E, Steins Bisschop CN, Los M, et al. Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study. BMJ open. 2017;7(3):e012187.
22.    McGuffin M, Merino T, Keller B, Pignol JP. Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017;29(3):e57-e63.
23.    Mercier G, Loureiro M, Georgescu V, Skalli EM, Nedelcu M, Ramadan M, et al. Surgical glue in laparoscopic sleeve gastrectomy: An initial experience and cost-effectiveness analysis. Journal of evaluation in clinical practice. 2017.
24.    Michael J, Crook J, Morton D, Batchelar D, Hilts M, Fenster A. Reply to: Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017.
25.    Moriwaki K, Mouri M, Hagino H. Erratum to: Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2017.
26.    Moriwaki K, Mouri M, Hagino H. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2017.
27.    Osterhoff G, O'Hara NN, D'Cruz J, Sprague SA, Bansback N, Evaniew N, et al. A Cost-Effectiveness Analysis of Reverse Total Shoulder Arthroplasty versus Hemiarthroplasty for the Management of Complex Proximal Humeral Fractures in the Elderly. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(3):404-11.
28.    Padula WV, Millis MA, Worku AD, Pronovost PJ, Bridges JF, Meltzer DO. Individualized cost-effectiveness analysis of patient-centered care: a case series of hospitalized patient preferences departing from practice-based guidelines. Journal of medical economics. 2017;20(3):288-96.
29.    Paquete AT, Miguel LS, Becker U, Pereira C, Pinto CG. Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy. Applied health economics and health policy. 2017.
30.    Pollock RF, Tikkanen CK. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. Journal of medical economics. 2017;20(3):213-20.
31.    Roberts K, Cannon J, Atkinson D, Brown A, Maguire G, Remenyi B, et al. Echocardiographic Screening for Rheumatic Heart Disease in Indigenous Australian Children: A Cost-Utility Analysis. Journal of the American Heart Association. 2017;6(3).
32.    Rodin D, Caulley L, Burger E, Kim J, Johnson-Obaseki S, Palma D, et al. Cost-Effectiveness Analysis of Radiation Therapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. International journal of radiation oncology, biology, physics. 2017;97(4):709-17.
33.    Rognoni C, Ciani O, Sommariva S, Tarricone R. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(3):336-44.
34.    Ruiz-Ramos J, Frasquet J, Roma E, Poveda-Andres JL, Salavert-Leti M, Catellanos A, et al. Cost-effectiveness analysis of implementing an antimicrobial stewardship programme in critical care units. Journal of medical economics. 2017:1-16.
35.    Sterne JA, Bodalia PN, Bryden PA, Davies PA, Lopez-Lopez JA, Okoli GN, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health technology assessment (Winchester, England). 2017;21(9):1-386.
36.    Tamoschus D, Draexler K, Chang J, Ngai C, Madin-Warburton M, Pitcher A. Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany. Clinical drug investigation. 2017.
37.    Thavorn K, Coyle D, Hoch JS, Vandermeer L, Mazzarello S, Wang Z, et al. A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017.
38.    Visser JJ, Oei EH, Hunink MG. Using Cost-Effectiveness Analysis to Measure Value in Musculoskeletal Imaging. Seminars in musculoskeletal radiology. 2017;21(1):37-42.
39.    Watt M, Dinh A, Le Monnier A, Tilleul P. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. Journal of medical economics. 2017:1-9.
40.    Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. International journal of chronic obstructive pulmonary disease. 2017;12:997-1008.
41.    Wu B, Zhang S, Lin H, Mou S. Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: a cost-effectiveness analysis. Journal of diabetes investigation. 2017.
42.    Wysham WZ, Schaffer EM, Coles T, Roque DR, Wheeler SB, Kim KH. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial. Gynecologic oncology. 2017.
43.    Xuan JW, Zhang ZY, Wang YF, Mao ZG, Lu YJ, Wang RZ. [Cost-effectiveness analysis of octreotide long acting release and lanreotide slow release for the treatment of postoperative patients with active acromegaly in China]. Zhonghua yi xue za zhi. 2017;97(10):765-9.


February 2017

1.    Bierbaum M, Schoffski O, Schliemann B, Kosters C. Cost-utility analysis of dynamic intraligamentary stabilization versus early reconstruction after rupture of the anterior cruciate ligament. Health economics review. 2017;7(1):8.
2.    Bugiantella W, Rondelli F, Mariani L, Polistena A, Sanguinetti A, Avenia N, et al. Cost-effectiveness analysis of the temporary percutaneous ileostomy for faecal diversion after colorectal resection in elderly. Aging clinical and experimental research. 2017;29(Suppl 1):47-53.
3.    Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I, et al. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology (Baltimore, Md). 2017.
4.    Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, et al. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. Journal of cancer research and clinical oncology. 2017;143(2):361-8.
5.    Connell NT, Abel GA, Connors JM. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. Thrombosis research. 2017;150:53-8.
6.    Cookson R, Mirelman AJ, Griffin S, Asaria M, Dawkins B, Norheim OF, et al. Using Cost-Effectiveness Analysis to Address Health Equity Concerns. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(2):206-12.
7.    Coppola A, D'Ausilio A, Aiello A, Amoresano S, Toumi M, Mathew P, et al. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. Haemophilia : the official journal of the World Federation of Hemophilia. 2017.
8.    Coyle D. Increasing the methodological quality and relevance of cost effectiveness analysis. Thrombosis research. 2017;150:121-2.
9.    Cradock AL, Barrett JL, Kenney EL, Giles CM, Ward ZJ, Long MW, et al. Using cost-effectiveness analysis to prioritize policy and programmatic approaches to physical activity promotion and obesity prevention in childhood. Preventive medicine. 2017;95s:S17-s27.
10.    de Jong LA, Dvortsin E, Janssen KJ, Postma MJ. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands. Clinical therapeutics. 2017;39(2):288-302.e4.
11.    Fontaine C, Daures JP, Landais P. On the censored cost-effectiveness analysis using copula information. BMC medical research methodology. 2017;17(1):27.
12.    Garrison LP, Jr., Kamal-Bahl S, Towse A. Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(2):213-6.
13.    Green AL, Gregory R. Cost-utility analysis alongside the PD SURG trial. Movement disorders : official journal of the Movement Disorder Society. 2017.
14.    Hansen KS, Ndyomugyenyi R, Magnussen P, Lal S, Clarke SE. Cost-effectiveness analysis of malaria rapid diagnostic tests for appropriate treatment of malaria at the community level in Uganda. Health policy and planning. 2017.
15.    Hassmiller Lich K, Cornejo DA, Mayorga ME, Pignone M, Tangka FK, Richardson LC, et al. Cost-Effectiveness Analysis of Four Simulated Colorectal Cancer Screening Interventions, North Carolina. Preventing chronic disease. 2017;14:E18.
16.    Heard C, Chaboyer W, Anderson V, Gillespie BM, Whitty JA. Cost-effectiveness analysis alongside a pilot study of prophylactic negative pressure wound therapy. Journal of tissue viability. 2017;26(1):79-84.
17.    Heinzel A, Muller D, Yekta-Michael SS, Ceccon G, Langen KJ, Mottaghy FM, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis. Neuro-oncology. 2017.
18.    Jenks M, Taylor M, Shore J. Cost-utility analysis of the insufflation of warmed humidified carbon dioxide during open and laparoscopic colorectal surgery. Expert review of pharmacoeconomics & outcomes research. 2017;17(1):99-107.
19.    Keller A, Gericke C, Whitty JA, Yaxley J, Kua B, Coughlin G, et al. A Cost-Utility Analysis of Prostate Cancer Screening in Australia. Applied health economics and health policy. 2017;15(1):95-111.
20.    Kotirum S, Chongmelaxme B, Chaiyakunapruk N. A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand. Journal of thrombosis and thrombolysis. 2017;43(2):252-62.
21.    Landfeldt E, Alfredsson L, Straub V, Lochmuller H, Bushby K, Lindgren P. Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis. PharmacoEconomics. 2017;35(2):249-58.
22.    Larsen B, Marcus B, Pekmezi D, Hartman S, Gilmer T. A Web-Based Physical Activity Intervention for Spanish-Speaking Latinas: A Costs and Cost-Effectiveness Analysis. Journal of medical Internet research. 2017;19(2):e43.
23.    Le P, Rothberg MB. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis. Journal of general internal medicine. 2017;32(2):159-67.
24.    Muhlbacher AC, Sadler A. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(2):266-72.
25.    Oksman E, Linna M, Horhammer I, Lammintakanen J, Talja M. Cost-effectiveness analysis for a tele-based health coaching program for chronic disease in primary care. BMC health services research. 2017;17(1):138.
26.    Pedersen K, Sorbye SW, Kristiansen IS, Burger EA. Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2017;124(3):474-84.
27.    Pepe A, Rossi G, Bentley A, Putti MC, Frizziero L, D'Ascola DG, et al. Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in beta-Thalassaemia Major Patients: An Italian Perspective. Clinical drug investigation. 2017.
28.    Qu XM, Louie AV, Ashman J, Wasif N. Cost-Effectiveness Analysis of Preoperative Versus Postoperative Radiation Therapy in Extremity Soft Tissue Sarcoma. International journal of radiation oncology, biology, physics. 2017;97(2):339-46.
29.    Schechner V, Carmeli Y, Leshno M. A mathematical model of Clostridium difficile transmission in medical wards and a cost-effectiveness analysis comparing different strategies for laboratory diagnosis and patient isolation. PloS one. 2017;12(2):e0171327.
30.    Seagle BL, Shahabi S. Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. Gynecologic oncology. 2017.
31.    Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, et al. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Current medical research and opinion. 2017;33(2):359-69.
32.    Simmons SF, Hollingsworth EK, Long EA, Liu X, Shotwell MS, Keeler E, et al. Training Nonnursing Staff to Assist with Nutritional Care Delivery in Nursing Homes: A Cost-Effectiveness Analysis. Journal of the American Geriatrics Society. 2017;65(2):313-22.
33.    Swart E, Laratta J, Slobogean G, Mehta S. Operative Treatment of Rib Fractures in Flail Chest Injuries: A Meta-analysis and Cost-Effectiveness Analysis. Journal of orthopaedic trauma. 2017;31(2):64-70.
34.    Teng AM, Kvizhinadze G, Nair N, McLeod M, Wilson N, Blakely T. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity. BMC infectious diseases. 2017;17(1):156.
35.    Twiner MJ, Marinica AL, Kuper K, Goodman A, Mahn JJ, Burla MJ, et al. Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost-effectiveness Analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2017;24(2):168-76.
36.    Vaidya V, Gangan N, Comerota A, Lurie F. Cost-Effectiveness Analysis of Initial Treatment Strategies for Nonembolic Acute Limb Ischemia Using Real-Word Data. Annals of vascular surgery. 2017;39:276-83.
37.    van Kampen RJ, Ramaekers BL, Lobbezoo DJ, de Boer M, Dercksen MW, van den Berkmortel F, et al. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. European journal of cancer (Oxford, England : 1990). 2017.
38.    Vinten A, Sample J, Ibiyemi A, Abdul-Salam Y, Stutter M. A tool for cost-effectiveness analysis of field scale sediment-bound phosphorus mitigation measures and application to analysis of spatial and temporal targeting in the Lunan Water catchment, Scotland. The Science of the total environment. 2017.
39.    Visser JJ, Oei EH, Hunink MG. Using Cost-Effectiveness Analysis to Measure Value in Musculoskeletal Imaging. Seminars in musculoskeletal radiology. 2017;21(1):37-42.
40.    Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2017;118(2):220-5.
41.    Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2017;28(2):643-52.


 January 2017

1.    Correction: Cost-Effectiveness Analysis of Test-Based versus Presumptive Treatment of Uncomplicated Malaria in Children under Five Years in an Area of High Transmission in Central Ghana. PloS one. 2017;12(1):e0170848.
2.    Albright CM, MacGregor C, Sutton D, Theva M, Hughes BL, Werner EF. Group B Streptococci Screening Before Repeat Cesarean Delivery: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2017;129(1):111-9.
3.    Baro E, Galperine T, Denies F, Lannoy D, Lenne X, Odou P, et al. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France. PloS one. 2017;12(1):e0170258.
4.    Breeze PR, Thomas C, Squires H, Brennan A, Greaves C, Diggle PJ, et al. The impact of Type 2 diabetes prevention programmes based on risk-identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis. Diabetic medicine : a journal of the British Diabetic Association. 2017.
5.    Canestaro W, Vodicka E, Downing D, Trussell J. Implications of employer coverage of contraception: Cost-effectiveness analysis of contraception coverage under an employer mandate. Contraception. 2017;95(1):77-89.
6.    Clement RC, Lang PJ, Pettett BJ, Overman RA, Ostrum RF, Tennant JN. Cost and Cost-effectiveness Analysis of Treatment Options for Sanders II and III Calcaneus Fractures In Laborers. Journal of orthopaedic trauma. 2017.
7.    de Jong LA, Dvortsin E, Janssen KJ, Postma MJ. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands. Clinical therapeutics. 2017.
8.    Dilokthornsakul P, Chaiyakunapruk N, Campbell JD. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter? The Journal of asthma : official journal of the Association for the Care of Asthma. 2017;54(1):17-23.
9.    Ekwunife OI, O'Mahony JF, Gerber Grote A, Mosch C, Paeck T, Lhachimi SK. Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations. PharmacoEconomics. 2017;35(1):65-82.
10.    Fernandes L, Roos EM, Overgaard S, Villadsen A, Sogaard R. Supervised neuromuscular exercise prior to hip and knee replacement: 12-month clinical effect and cost-utility analysis alongside a randomised controlled trial. BMC musculoskeletal disorders. 2017;18(1):5.
11.    Germar MJ, Purugganan C, Bernardino MS, Cuenca B, Chen YC, Li X, et al. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule. Human vaccines & immunotherapeutics. 2017:0.
12.    Gimeno-Ballester V, Mar J, O'Leary A, Adams R, San Miguel R. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert review of gastroenterology & hepatology. 2017;11(1):85-93.
13.    Goyert N, Eeson G, Kagedan DJ, Behman R, Lemke M, Hallet J, et al. Pasireotide for the Prevention of Pancreatic Fistula Following Pancreaticoduodenectomy: A Cost-effectiveness Analysis. Annals of surgery. 2017;265(1):2-10.
14.    Grau S, Azanza JR, Ruiz I, Vallejo C, Mensa J, Maertens J, et al. Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain. ClinicoEconomics and outcomes research : CEOR. 2017;9:39-47.
15.    Grover R, Rueda S, Gurunluoglu R. Letter to Editor: Is Single-Stage Prosthetic Reconstruction Cost effective? A Cost-Utility Analysis for the Use of Direct-to-Implant Breast Reconstruction Relative to Expander-Implant Reconstruction in Postmastectomy Patients. Plastic and reconstructive surgery. 2017.
16.    Hansen TB, Zwisler AD, Berg SK, Sibilitz KL, Thygesen LC, Kjellberg J, et al. Cost-utility analysis of cardiac rehabilitation after conventional heart valve surgery versus usual care. European journal of preventive cardiology. 2017:2047487317689908.
17.    Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, et al. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Advances in therapy. 2017;34(1):207-20.
18.    Huang QC, Ye D, Jiang XY, Li QL, Yao KY, Wang JB, et al. [Cost-effectiveness analysis on colorectal cancer screening program]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2017;38(1):65-8.
19.    Idrisov B, Murphy SM, Morrill T, Saadoun M, Lunze K, Shepard D. Implementation of methadone therapy for opioid use disorder in Russia - a modeled cost-effectiveness analysis. Substance abuse treatment, prevention, and policy. 2017;12(1):4.
20.    Igarashi A, Tang W, Cure S, Guerra I, Marie L, Lopresti M, et al. Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. Current medical research and opinion. 2017;33(1):1-10.
21.    Igarashi A, Tang W, Guerra I, Marie L, Cure S, Lopresti M. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Current medical research and opinion. 2017;33(1):11-21.
22.    Isaranuwatchai W, Alam F, Hoch J, Boet S. A cost-effectiveness analysis of self-debriefing versus instructor debriefing for simulated crises in perioperative medicine in Canada. Journal of educational evaluation for health professions. 2017;13:44.
23.    Kimura T, Igarashi A, Ikeda S, Nakajima K, Kashimura S, Kunitomi A, et al. A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan. Journal of cardiology. 2017;69(1):89-97.
24.    Krishnan NM, Fischer JP, Basta MN, Nahabedian MY. Is Single-Stage Prosthetic Reconstruction Cost Effective? A Cost Utility Analysis for the use of Direct-to-Implant Breast Reconstruction Relative to Expander-Implant Reconstruction in Post-Mastectomy Patients. Plastic and reconstructive surgery. 2017.
25.    Kulchaitanaroaj P, Brooks JM, Chaiyakunapruk N, Goedken AM, Chrischilles EA, Carter BL. Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. Journal of hypertension. 2017;35(1):178-87.
26.    Lam SW, Wai M, Lau JE, McNamara M, Earl M, Udeh B. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer. Pharmacotherapy. 2017;37(1):94-103.
27.    Lapointe-Shaw L, Voruganti T, Kohler P, Thein HH, Sander B, McGeer A. Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2017.
28.    McFarland A. A cost utility analysis of the clinical algorithm for nasogastric tube placement confirmation in adult hospital patients. Journal of advanced nursing. 2017;73(1):201-16.
29.    Nerich V, Fleck C, Chaigneau L, Isambert N, Borg C, Kalbacher E, et al. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors. Clinical drug investigation. 2017;37(1):85-94.
30.    Neumann PJ, Sanders GD. Cost-Effectiveness Analysis 2.0. The New England journal of medicine. 2017;376(3):203-5.
31.    Parker C, Woods B, Eaton J, Ma E, Selby R, Benson E, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. Journal of medical economics. 2017;20(1):8-18.
32.    Rivera F, Valladares M, Gea S, Lopez-Martinez N. Cost-effectiveness analysis in the Spanish setting of the peak trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Journal of medical economics. 2017:1-27.
33.    Scangas GA, Remenschneider AK, Su BM, Shrime MG, Metson R. Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyposis. The Laryngoscope. 2017;127(1):29-37.
34.    Sheng G, Chen S, Dong C, Zhang R, Miao M, Wu D, et al. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis. Journal of medical economics. 2017:1-11.
35.    Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, et al. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. Clinical lung cancer. 2017;18(1):e41-e7.
36.    Yang MC, Tan EC, Su JJ. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model. Human vaccines & immunotherapeutics. 2017;13(1):81-9.
37.    Zanocco KA, Wu JX, Yeh MW. Parathyroidectomy for asymptomatic primary hyperparathyroidism: A revised cost-effectiveness analysis incorporating fracture risk reduction. Surgery. 2017;161(1):16-24.
38.    Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA. A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK. The European journal of health economics : HEPAC : health economics in prevention and care. 2017.


December 2016

1.    Berm EJ, Gout-Zwart JJ, Luttjeboer J, Wilffert B, Postma MJ. A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy. PloS one. 2016;11(12):e0169065.
2.    Bohensky MA, Pasupathi K, Gorelik A, Kim H, Harrison JP, Liew D. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2016;19(8):1009-15.
3.    Castro Jaramillo HE, Moreno Viscaya M, Mejia AE. COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA. International journal of technology assessment in health care. 2016;32(5):337-47.
4.    Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, et al. Directly acting antivirals combination for elderly patients with Chronic Hepatitis C: a Cost-Effectiveness Analysis. Liver international : official journal of the International Association for the Study of the Liver. 2016.
5.    Connell NT, Abel GA, Connors JM. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. Thrombosis research. 2016;150:53-8.
6.    Cotton CC, Erim D, Eluri S, Palmer SH, Green DJ, Wolf WA, et al. Cost Utility Analysis of Topical Steroids Compared to Dietary Elimination for Treatment of Eosinophilic Esophagitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2016.
7.    Coyle D. Increasing the methodological quality and relevance of cost effectiveness analysis. Thrombosis research. 2016.
8.    Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, et al. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. PharmacoEconomics. 2016.
9.    Garrison LP, Jr., Zimmermann MR, Young CH, Crittendon J, Genereux P. Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-up. Cardiovascular revascularization medicine : including molecular interventions. 2016.
10.    Glassman A, Canon O, Silverman R. How to Get Cost-Effectiveness Analysis Right? The Case of Vaccine Economics in Latin America. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2016;19(8):913-20.
11.    Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, et al. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Advances in therapy. 2017;34(1):207-20.
12.    Isaranuwatchai W, Alam F, Hoch J, Boet S. A cost-effectiveness analysis of self-debriefing versus instructor debriefing for simulated crises in perioperative medicine in Canada. Journal of educational evaluation for health professions. 2017;13:44.
13.    Jenks M, Taylor M, Shore J. Cost-utility analysis of the insufflation of warmed humidified carbon dioxide during open and laparoscopic colorectal surgery. Expert review of pharmacoeconomics & outcomes research. 2016:1-9.
14.    Jiang M, You JH. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Cardiovascular drugs and therapy. 2016.
15.    Liu CY, Chen HC. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan. Clinical drug investigation. 2016.
16.    McGuffin M, Merino T, Keller B, Pignol JP. Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 2016.
17.    Mohiuddin S, Reeves B, Pufulete M, Maishman R, Dayer M, Macleod J, et al. Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. BMJ open. 2016;6(12):e014010.
18.    Mohr NM, Stoltze A, Ahmed A, Kiscaden E, Shane D. Using continuous quantitative capnography for emergency department procedural sedation: a systematic review and cost-effectiveness analysis. Internal and emergency medicine. 2016.
19.    Pinsky MR, Valentin A, Rubenfeld G. Intensive Care Medicine in 2050: cost-effectiveness analysis. Intensive care medicine. 2016.
20.    Restelli U, Alberti A, Lazzarin A, Bonfanti M, Nappi C, Croce D. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. The European journal of health economics : HEPAC : health economics in prevention and care. 2016.
21.    Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, et al. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. PharmacoEconomics. 2016.
22.    Shiffman D, Arellano AR, Caulfield MP, Louie JZ, Bare LA, Devlin JJ, et al. Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis. BMC cardiovascular disorders. 2016;16(1):251.
23.    Tan J, Liu L, Xie J, Hu L, Yang Q, Wang H. Cost-effectiveness analysis of ultrasound-guided Seldinger peripherally inserted central catheters (PICC). SpringerPlus. 2016;5(1):2051.
24.    Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2016.


November 2016

1.    Bugiantella W, Rondelli F, Mariani L, Polistena A, Sanguinetti A, Avenia N, et al. Cost-effectiveness analysis of the temporary percutaneous ileostomy for faecal diversion after colorectal resection in elderly. Aging clinical and experimental research. 2016.
2.    Bustillo-Lecompte CF, Mehrvar M. Treatment of an actual slaughterhouse wastewater by integration of biological and advanced oxidation processes: Modeling, optimization, and cost-effectiveness analysis. Journal of environmental management. 2016;182:651-66.
3.    Ceballos M, Orozco LE, Valderrama CO, Londono DI, Lugo LH. Cost-effectiveness analysis of the use of a prophylactic antibiotic for patients undergoing lower limb amputation due to diabetes or vascular illness in Colombia. Annals of vascular surgery. 2016.
4.    Cui S, Tobe RG, Mo X, Liu X, Xu L, Li S. Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option. BMC infectious diseases. 2016;16(1):677.
5.    Davidson C. Uncertainty in evidence synthesis limits clinical applicability of a clinical and cost-effectiveness analysis of induction of labour methods. Evidence-based medicine. 2016;21(6):226.
6.    Delgleize E, Leeuwenkamp O, Theodorou E, Van de Velde N. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model. BMJ open. 2016;6(11):e010776.
7.    Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, et al. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast cancer research and treatment. 2016;160(1):187-96.
8.    Gama E, Were V, Ouma P, Desai M, Niessen L, Buff AM, et al. Large-scale implementation of disease control programmes: a cost-effectiveness analysis of long-lasting insecticide-treated bed net distribution channels in a malaria-endemic area of western Kenya-a study protocol. BMJ open. 2016;6(11):e012776.
9.    Greenberg D, Neumann PJ. Cost-Effectiveness Analysis Expands its Reach Worldwide. Value in health regional issues. 2016;10:101-2.
10.    Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq SF. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. Journal of medical economics. 2016:1-11.
11.    Iannazzo S, Cortesi PA, Crea R, Steinitz K, Mantovani LG, Gringeri A. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2016.
12.    Ke W, Zhang C, Liu L, Gao Y, Yao Z, Ye X, et al. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Hepatology international. 2016;10(6):924-36.
13.    Kelly RJ, Smith TJ. Checkpoint Inhibitors in Lung Cancer Are Not Immune from Cost-Effectiveness Analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(11):1814-6.
14.    Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric Surgery for Nonalcoholic Steatohepatitis: A Clinical and Cost-Effectiveness Analysis. Hepatology (Baltimore, Md). 2016.
15.    Lam SW, Wai M, Lau JE, McNamara M, Earl M, Udeh B. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer. Pharmacotherapy. 2016.
16.    Lee D, Park SM. Cost-Effectiveness Analysis of Hepatitis B Vaccination Strategies to Prevent Perinatal Transmission in North Korea: Selective Vaccination vs. Universal Vaccination. PloS one. 2016;11(11):e0165879.
17.    Lee HD, Jeon CH, Chung NS, Seo YW. Cost-Utility Analysis of Pedicle Screw Removal after Successful Posterior Instrumented Fusion in Thoracolumbar Burst Fractures. Spine. 2016.
18.    Luttjeboer J, Setiawan D, Cao Q, Cahh Daemen T, Postma MJ. Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands. Vaccine. 2016;34(50):6381-7.
19.    Mantopoulos T, Mitchell PM, Welton NJ, McManus R, Andronis L. Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results. The European journal of health economics : HEPAC : health economics in prevention and care. 2016;17(8):927-38.
20.    Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, et al. A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(11):1846-55.
21.    Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Alimentary pharmacology & therapeutics. 2016;44(10):1090-101.
22.    Nogueira TE, Esfandiari S, Leles CR. Cost-effectiveness analysis of the single-implant mandibular overdenture versus conventional complete denture: study protocol for a randomized controlled trial. Trials. 2016;17(1):533.
23.    Padula WV, Millis MA, Worku AD, Pronovost PJ, Bridges JF, Meltzer DO. Individualized cost-effectiveness analysis of patient-centered care: a case series of hospitalized patient preferences departing from practice-based guidelines. Journal of medical economics. 2016:1-9.
24.    Park KW, Boyer MI, Gelberman RH, Calfee RP, Stepan JG, Osei DA. Simultaneous Bilateral Versus Staged Bilateral Carpal Tunnel Release: A Cost-effectiveness Analysis. The Journal of the American Academy of Orthopaedic Surgeons. 2016;24(11):796-804.
25.    Park SK, Park SH, Lee MY, Park JH, Jeong JH, Lee EK. Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. Clinical therapeutics. 2016;38(11):2430-46.e3.
26.    Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, et al. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Current medical research and opinion. 2016:1-11.
27.    Shim E. Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines. The American journal of tropical medicine and hygiene. 2016;95(5):1137-47.
28.    Silverstein A, Costas-Chavarri A, Gakwaya MR, Lule J, Mukhopadhyay S, Meara JG, et al. Laparoscopic Versus Open Cholecystectomy: A Cost-Effectiveness Analysis at Rwanda Military Hospital. World journal of surgery. 2016.
29.    Stawowczyk E, Kawalec P, Pilc A. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland. European journal of clinical pharmacology. 2016;72(11):1319-25.
30.    Tonmukayakul U, Arrow P. Cost-effectiveness analysis of the atraumatic restorative treatment-based approach to managing early childhood caries. Community dentistry and oral epidemiology. 2016.
31.    Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, et al. Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy. European journal of cancer (Oxford, England : 1990). 2016;67:38-45.
32.    Wen F, Zheng H, Wu Y, Wheeler J, Zeng X, Fu P, et al. Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma. Scientific reports. 2016;6:36060.
33.    Wilkinson A, Anderson S, Wheeler SB. Screening for and Treating Postpartum Depression and Psychosis: A Cost-Effectiveness Analysis. Maternal and child health journal. 2016.
34.    Zanocco KA, Wu JX, Yeh MW. Parathyroidectomy for asymptomatic primary hyperparathyroidism: A revised cost-effectiveness analysis incorporating fracture risk reduction. Surgery. 2016.


October 2016

1.    Landfeldt E, Alfredsson L, Straub V, Lochmuller H, Bushby K, Lindgren P. Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis. PharmacoEconomics. 2016.
2.    Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, et al. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. Journal of cancer research and clinical oncology. 2016.
3.    El Alaoui S, Lindefors N. Combining Time-Driven Activity-Based Costing with Clinical Outcome in Cost-Effectiveness Analysis to Measure Value in Treatment of Depression. PloS one. 2016;11(10):e0165389.
4.    Twiner MJ, Marinica AL, Kuper K, Goodman A, Mahn JJ, Burla MJ, et al. Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost Effectiveness Analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2016.
5.    Padula WV, Millis MA, Worku AD, Pronovost PJ, Bridges JF, Meltzer DO. Individualized cost-effectiveness analysis of patient-centered care: a case series of hospitalized patient preferences departing from practice-based guidelines. Journal of medical economics. 2016:1-19.
6.    Tsukiyama I, Ejiri M, Yamamoto Y, Nakao H, Yoneda M, Matsuura K, et al. A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan. Journal of gastrointestinal cancer. 2016.
7.    Smajerova M, Petrasova H, Little J, Ovesna P, Andrasina T, Valek V, et al. Contrast-enhanced ultrasonography in the evaluation of incidental focal liver lesions: A cost-effectiveness analysis. World journal of gastroenterology. 2016;22(38):8605-14.
8.    Stevanovic J, de Jong LA, Kappelhoff BS, Dvortsin EP, Voorhaar M, Postma MJ. Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands. PloS one. 2016;11(10):e0163550.
9.    Cradock AL, Barrett JL, Kenney EL, Giles CM, Ward ZJ, Long MW, et al. Using cost-effectiveness analysis to prioritize policy and programmatic approaches to physical activity promotion and obesity prevention in childhood. Preventive medicine. 2016.
10.    Park SK, Park SH, Lee MY, Park JH, Jeong JH, Lee EK. Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. Clinical therapeutics. 2016.
11.    Soini E, Hallinen T, Brignone M, Campbell R, Diamand F, Cure S, et al. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert review of pharmacoeconomics & outcomes research. 2016:1-10.
12.    Liu CC, Rudmik L. A Cost-effectiveness Analysis of Early vs Late Tracheostomy. JAMA otolaryngology-- head & neck surgery. 2016;142(10):981-7.
13.    Keller A, Gericke C, Whitty JA, Yaxley J, Kua B, Coughlin G, et al. A Cost-Utility Analysis of Prostate Cancer Screening in Australia. Applied health economics and health policy. 2016.
14.    Karnon J, Shafie AS, Orji N, Usman SK. What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia. Cost effectiveness and resource allocation : C/E. 2016;14:11.
15.    Le P, Rothberg MB. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis. Journal of general internal medicine. 2016.
16.    Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2016.
17.    Rocke DJ, Goldstein DP, de Almeida JR. A Cost-Utility Analysis of Recurrent Laryngeal Nerve Monitoring in the Setting of Total Thyroidectomy. JAMA otolaryngology-- head & neck surgery. 2016.
18.    Mason SE, Kinross JM, Hendricks J, Arulampalam TH. Postoperative hypothermia and surgical site infection following peritoneal insufflation with warm, humidified carbon dioxide during laparoscopic colorectal surgery: a cohort study with cost-effectiveness analysis. Surgical endoscopy. 2016.
19.    Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq SF. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. Journal of medical economics. 2016:1-29.
20.    Odnoletkova I, Ramaekers D, Nobels F, Goderis G, Aertgeerts B, Annemans L. Delivering Diabetes Education through Nurse-Led Telecoaching. Cost-Effectiveness Analysis. PloS one. 2016;11(10):e0163997.
21.    Gordon LG, James R, Tuffaha HW, Lowe A, Yaxley J. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia. Journal of magnetic resonance imaging : JMRI. 2016.
22.    Walusimbi S, Kwesiga B, Rodrigues R, Haile M, de Costa A, Bogg L, et al. Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda. BMC health services research. 2016;16(1):563.
23.    Pollock RF, Tikkanen CK. A short-term cost-utility analysis of insulin degludec versus insulin glargine in patients with type 1 or type 2 diabetes in Denmark. Journal of medical economics. 2016:1-19.
24.    Kotirum S, Chongmelaxme B, Chaiyakunapruk N. A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand. Journal of thrombosis and thrombolysis. 2016.
25.    Tawiah T, Hansen KS, Baiden F, Bruce J, Tivura M, Delimini R, et al. Cost-Effectiveness Analysis of Test-Based versus Presumptive Treatment of Uncomplicated Malaria in Children under Five Years in an Area of High Transmission in Central Ghana. PloS one. 2016;11(10):e0164055.
26.    Smith AF, Sutton A, Shinkins B. EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS: RESPONSE. International journal of technology assessment in health care. 2016:1-2.
27.    Korolija Marinic D, Varga S. Cost Utility Analysis Of Selected Medical Equipment And Procedures In Croatia. Clinical therapeutics. 2016;38(10s):e15.
28.    Dottino JA, Hasselblad V, Secord AA, Myers ER, Chino J, Havrilesky LJ. Levonorgestrel Intrauterine Device as an Endometrial Cancer Prevention Strategy in Obese Women: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2016;128(4):747-53.
29.    Picot MC, Jaussent A, Neveu D, Kahane P, Crespel A, Gelisse P, et al. Cost-effectiveness analysis of epilepsy surgery in a controlled cohort of adult patients with intractable partial epilepsy: A 5-year follow-up study. Epilepsia. 2016;57(10):1669-79.
30.    Fallah A, Weil AG, Wang S, Lewis E, Baca CB, Mathern GW. Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with Tuberous Sclerosis Complex. Epilepsy & behavior : E&B. 2016;63:79-88.
31.    Le QA, Bae YH, Kang JH. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast cancer research and treatment. 2016;159(3):565-73.
32.    Zimovetz EA, Beard SM, Hodgkins P, Bischof M, Mauskopf JA, Setyawan J. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate. CNS drugs. 2016;30(10):985-96.
33.    Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, Ternouth A, Miravitlles M, Rutten-van Molken M, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat(R) fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Therapeutic advances in respiratory disease. 2016;10(5):391-401.
34.    Taylor C, Thompson K, Finfer S, Higgins A, Jan S, Li Q, et al. Hydroxyethyl starch versus saline for resuscitation of patients in intensive care: long-term outcomes and cost-effectiveness analysis of a cohort from CHEST. The Lancet Respiratory medicine. 2016;4(10):818-25.
35.    Yun BJ, Myriam Hunink MG, Prabhakar AM, Heng M, Liu SW, Qudsi R, et al. Diagnostic Imaging Strategies for Occult Hip Fractures: A Decision and Cost-Effectiveness Analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2016;23(10):1161-9.
36.    Penaloza-Ramos MC, Jowett S, Barton P, Roalfe A, Fletcher K, Taylor CJ, et al. Cost-effectiveness analysis of different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack: Economic analysis of the PAST-BP study. European journal of preventive cardiology. 2016;23(15):1590-8.
37.    Qureshi N, Weng S, Hex N. The role of cost-effectiveness analysis in the development of indicators to support incentive-based behaviour in primary care in England. Journal of health services research & policy. 2016;21(4):263-71.
38.    Muduma G, Odeyemi I, Pollock RF. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. Journal of medical economics. 2016;19(10):995-1002.
39.    Angulo JC, Sanchez-Ballester F, Peral C, Rejas J, Ramos J, Snedecor SJ, et al. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective. Actas urologicas espanolas. 2016;40(8):513-22.
40.    Gibbons JP, Nugent E, O'Donohoe N, Maher B, Egan B, Feeley M, et al. Experience with botulinum toxin therapy for axillary hyperhidrosis and comparison to modelled data for endoscopic thoracic sympathectomy - A quality of life and cost effectiveness analysis. The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland. 2016;14(5):260-4.


September 2016

1.    Cost-Effectiveness Analysis of the Use of Probiotics for the Prevention of Clostridium difficile-Associated Diarrhea in a Provincial Healthcare System - ERRATUM. Infection control and hospital epidemiology. 2016;37(9):1133.
2.    Ahmadiani S, Nikfar S, Karimi S, Jamshidi AR, Akbari-Sari A, Kebriaeezadeh A. Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis. Rheumatology international. 2016;36(9):1291-300.
3.    Arrieta O, Anaya P, Morales-Oyarvide V, Ramirez-Tirado LA, Polanco AC. Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel. The European journal of health economics : HEPAC : health economics in prevention and care. 2016;17(7):855-63.
4.    Babu MA. Commentary: Surgical Management of the Elderly With Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. Neurosurgery. 2016;79(3):426-7.
5.    Burgers LT, Redekop WK, Al MJ, Lhachimi SK, Armstrong N, Walker S, et al. Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients. The European journal of health economics : HEPAC : health economics in prevention and care. 2016.
6.    Canestaro WJ. Capsule Commentary on Phibbs et. al., At-Home versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). Journal of general internal medicine. 2016;31(9):1082.
7.    Chalayer E, Bourmaud A, Tinquaut F, Chauvin F, Tardy B. Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma. Thrombosis research. 2016;145:119-25.
8.    Chang HW, Shin SH, Suh SH, Kim BS, Rho MH. Cost-Effectiveness Analysis of Endovascular Coiling versus Neurosurgical Clipping for Intracranial Aneurysms in Republic of Korea. Neurointervention. 2016;11(2):86-91.
9.    Coretti S, Codella P, Romano F, Ruggeri M, Cicchetti A. COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS. International journal of technology assessment in health care. 2016:1-8.
10.    Cromwell I, Regier DA, Peacock SJ, Poh CF. Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada. The oncologist. 2016;21(9):1099-106.
11.    Cui M, Tu CC, Chen EZ, Wang XL, Tan SC, Chen C. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China. Advances in therapy. 2016;33(9):1600-11.
12.    Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, et al. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast cancer research and treatment. 2016;160(1):187-96.
13.    Donovan P, McLeod D, Little R, Gordon L. Cost-Utility Analysis Comparing Radioactive Iodine, Antithyroid Drugs and Total Thyroidectomy for Primary Treatment of Graves' Disease. European journal of endocrinology. 2016.
14.    Ekwunife OI, O'Mahony JF, Gerber Grote A, Mosch C, Paeck T, Lhachimi SK. Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations. PharmacoEconomics. 2016.
15.    Freemantle N, Khalaf K, Loveman C, Stanisic S, Gultyaev D, Lister J, et al. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales. The European journal of health economics : HEPAC : health economics in prevention and care. 2016;17(7):911-21.
16.    Fukuda H, Moriwaki K. Cost-Effectiveness Analysis of Safety-Engineered Devices. Infection control and hospital epidemiology. 2016;37(9):1012-21.
17.    Furlan JC, Craven BC, Fehlings MG. Surgical Management of the Elderly With Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. Neurosurgery. 2016;79(3):418-25.
18.    Garcia A, Ortiz de Lejarazu R, Reina J, Callejo D, Cuervo J, Morano Larragueta R. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain. Human vaccines & immunotherapeutics. 2016;12(9):2269-77.
19.    Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, et al. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA cardiology. 2016;1(6):666-72.
20.    Georgalis L, de Sanjose S, Esnaola M, Bosch FX, Diaz M. Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). 2016;25(5):430-9.
21.    Green W, Taylor M. Cost-Effectiveness Analysis of d-Nav for People with Diabetes at High Risk of Neuropathic Foot Ulcers. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2016;7(3):511-25.
22.    Hahn-Pedersen J, Worm M, Green W, Andreasen JN, Taylor M. Cost utility analysis of the SQ((R)) HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting. Clinical and translational allergy. 2016;6(1):35.
23.    Hojjat H, Svider PF, Davoodian P, Hong RS, Folbe AJ, Eloy JA, et al. To image or not to image? A cost-effectiveness analysis of MRI for patients with asymmetric sensorineural hearing loss. The Laryngoscope. 2016.
24.    Igarashi A, Tang W, Cure S, Guerra I, Marie L, Lopresti M, et al. Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. Current medical research and opinion. 2016:1-10.
25.    Igarashi A, Tang W, Guerra I, Marie L, Cure S, Lopresti M. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Current medical research and opinion. 2016:1-11.
26.    Kang JR, Sin AT, Cheung EV. Treatment of Massive Irreparable Rotator Cuff Tears: A Cost-effectiveness Analysis. Orthopedics. 2016:1-12.
27.    Kempfle JS, BuSaba NY, Dobrowski JM, Westover MB, Bianchi MT. A cost-effectiveness analysis of nasal surgery to increase continuous positive airway pressure adherence in sleep apnea patients with nasal obstruction. The Laryngoscope. 2016.
28.    Krishnan NM, Fischer JP, Basta MN, Nahabedian MY. Is Single-Stage Prosthetic Reconstruction Cost Effective? A Cost-Utility Analysis for the Use of Direct-to-Implant Breast Reconstruction Relative to Expander-Implant Reconstruction in Postmastectomy Patients. Plastic and reconstructive surgery. 2016;138(3):537-47.
29.    Kulchaitanaroaj P, Brooks JM, Chaiyakunapruk N, Goedken AM, Chrischilles EA, Carter BL. Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. Journal of hypertension. 2016.
30.    Kuznik A, Iliyasu G, Habib AG, Musa BM, Kambugu A, Lamorde M. Initiation of antiretroviral therapy based on the 2015 WHO guidelines: A cost-effectiveness analysis in Nigeria, South Africa, Uganda and India. AIDS (London, England). 2016.
31.    Lanzeta I, Mar J, Arrospide A. Cost-utility analysis of an integrated care model for multimorbid patients based on a clinical trial. Gaceta sanitaria / SESPAS. 2016;30(5):352-8.
32.    Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M. Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. The Journal of infectious diseases. 2016;214(5):685-8.
33.    Launio CC, Asis CA, Manalili RG, Javier EF. Cost-effectiveness analysis of farmers' rice straw management practices considering CH4 and N2O emissions. Journal of environmental management. 2016;183:245-52.
34.    Leal JR, Heitman SJ, Conly JM, Henderson EA, Manns BJ. Cost-Effectiveness Analysis of the Use of Probiotics for the Prevention of Clostridium difficile-Associated Diarrhea in a Provincial Healthcare System. Infection control and hospital epidemiology. 2016;37(9):1079-86.
35.    Lindkvist M, Feldman I. Assessing outcomes for cost-utility analysis in mental health interventions: mapping mental health specific outcome measure GHQ-12 onto EQ-5D-3L. Health and quality of life outcomes. 2016;14(1):134.
36.    Machado de Assis TS, Azeredo-da-Silva AL, Werneck GL, Rabello A. Cost-effectiveness analysis of diagnostic tests for human visceral leishmaniasis in Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2016;110(8):464-71.
37.    Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis. Journal of medical genetics. 2016;53(9):591-9.
38.    Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, et al. Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis. Drug safety. 2016;39(9):859-72.
39.    Neary KC, Mormino MA, Wang H. Suture Button Fixation Versus Syndesmotic Screws in Supination-External Rotation Type 4 Injuries: A Cost-Effectiveness Analysis. The American journal of sports medicine. 2016.
40.    Nerich V, Fleck C, Chaigneau L, Isambert N, Borg C, Kalbacher E, et al. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors. Clinical drug investigation. 2016.
41.    Nichols BE, Boucher CA, van der Valk M, Rijnders BJ, van de Vijver DA. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. The Lancet Infectious diseases. 2016.
42.    Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Alimentary pharmacology & therapeutics. 2016.
43.    Park KW, Boyer MI, Gelberman RH, Calfee RP, Stepan JG, Osei DA. Simultaneous Bilateral Versus Staged Bilateral Carpal Tunnel Release: A Cost-effectiveness Analysis. The Journal of the American Academy of Orthopaedic Surgeons. 2016.
44.    Pearson-Stuttard J, Hooton W, Critchley J, Capewell S, Collins M, Mason H, et al. Cost-effectiveness analysis of eliminating industrial and all trans fats in England and Wales: modelling study. Journal of public health (Oxford, England). 2016.
45.    Phibbs CS, Love SR, Jacobson AK, Edson R, Su P, Uyeda L, et al. At-Home Versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). Journal of general internal medicine. 2016;31(9):1061-7.
46.    Picot MC, Jaussent A, Neveu D, Kahane P, Crespel A, Gelisse P, et al. Cost-effectiveness analysis of epilepsy surgery in a controlled cohort of adult patients with intractable partial epilepsy: A 5-year follow-up study. Epilepsia. 2016.
47.    Ramponi F, Ronco C, Mason G, Rettore E, Marcelli D, Martino F, et al. Cost-effectiveness analysis of online hemodiafiltration versus high-flux hemodialysis. ClinicoEconomics and outcomes research : CEOR. 2016;8:531-40.
48.    Roberts MS. The Next Chapter in Cost-effectiveness Analysis. Jama. 2016;316(10):1049-50.
49.    Ruiz-Sanchez D, Peinado, II, Alaguero-Calero M, Sastre-Heres AJ, Diez BG, Pena-Diaz J. Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences. Oncology letters. 2016;12(3):1935-40.
50.    Serra-Arbeloa P, Rabines-Juarez AO, Alvarez-Ruiz MS, Guillen-Grima F. Sentinel node biopsy in patients with primary cutaneous melanoma of any thickness: A cost-effectiveness analysis. Surgical oncology. 2016;25(3):205-11.
51.    Shim E. Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines. The American journal of tropical medicine and hygiene. 2016.
52.    Siribumrungwong B, Noorit P, Wilasrusmee C, Leelahavarong P, Thakkinstian A, Teerawattananon Y. Cost-utility analysis of great saphenous vein ablation with radiofrequency, foam and surgery in the emerging health-care setting of Thailand. Phlebology / Venous Forum of the Royal Society of Medicine. 2016;31(8):573-81.
53.    Sohn M, Talbert J, Moga DC, Blumenschein K. A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy. Attention deficit and hyperactivity disorders. 2016;8(3):149-58.
54.    Soini E, Hallinen T, Brignone M, Campbell R, Diamand F, Cure S, et al. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert review of pharmacoeconomics & outcomes research. 2016.
55.    Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, et al. Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy. European journal of cancer (Oxford, England : 1990). 2016;67:38-45.
56.    Verguet S, Kim JJ, Jamison DT. Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. PharmacoEconomics. 2016;34(9):913-23.
57.    Visco AG, Zyczynski H, Brubaker L, Nygaard I, Xu X, Lukacz ES, et al. Cost-Effectiveness Analysis of Anticholinergics Versus Botox for Urgency Urinary Incontinence: Results From the Anticholinergic Versus Botox Comparison Randomized Trial. Female pelvic medicine & reconstructive surgery. 2016;22(5):311-6.
58.    Yang MC, Tan EC, Su JJ. Cost-Effectiveness Analysis of Quadrivalent versus Trivalent Influenza Vaccine in Taiwan: A Lifetime Multi-Cohort Model. Human vaccines & immunotherapeutics. 2016:0.


August 2016

1.    Fallah A, Weil AG, Wang S, Lewis E, Baca CB, Mathern GW. Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with Tuberous Sclerosis Complex. Epilepsy & behavior : E&B. 2016;63:79-88.
2.    Alfirevic Z, Keeney E, Dowswell T, Welton NJ, Medley N, Dias S, et al. Which method is best for the induction of labour? A systematic review, network meta-analysis and cost-effectiveness analysis. Health technology assessment (Winchester, England). 2016;20(65):1-584.
3.    Lee VW, Tsai RB, Chow IH, Yan BP, Kaya MG, Park JW, et al. Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation. BMC cardiovascular disorders. 2016;16(1):167.
4.    de Jong PH, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, et al. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial. Rheumatology (Oxford, England). 2016.
5.    Vaidya V, Gangan N, Comerota A, Lurie F. Cost-effectiveness analysis of initial treatment strategies for nonembolic acute limb ischemia using real word data. Annals of vascular surgery. 2016.
6.    Zhang H, Huo M, Chao J, Liu P. Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B. PloS one. 2016;11(8):e0161936.
7.    Le QA, Bae YH, Kang JH. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast cancer research and treatment. 2016.
8.    Bustillo-Lecompte CF, Mehrvar M. Treatment of an actual slaughterhouse wastewater by integration of biological and advanced oxidation processes: Modeling, optimization, and cost-effectiveness analysis. Journal of environmental management. 2016;182:651-66.
9.    Drabo EF, Hay JW, Vardavas R, Wagner ZR, Sood N. A Cost-Effectiveness Analysis Of Pre-Exposure Prophylaxis For The Prevention Of HIV Among Los Angeles County Men Who Have Sex With Men. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016.
10.    Acevedo JR, Fero KE, Wilson B, Sacco AG, Mell LK, Coffey CS, et al. Cost-Effectiveness Analysis of Elective Neck Dissection in Patients With Clinically Node-Negative Oral Cavity Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016.
11.    Canestaro W, Vodicka E, Downing D, Trussell J. Implications of Employer Coverage of Contraception: Cost-Effectiveness Analysis of Contraception Coverage Under an Employer Mandate. Contraception. 2016.
12.    Goyert N, Eeson G, Kagedan DJ, Behman R, Lemke M, Hallet J, et al. Pasireotide for the Prevention of Pancreatic Fistula Following Pancreaticoduodenectomy: A Cost-effectiveness Analysis. Annals of surgery. 2016.
13.    Chalayer E, Bourmaud A, Tinquaut F, Chauvin F, Tardy B. Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma. Thrombosis research. 2016;145:119-25.
14.    Shemilt I, Khan N, Park S, Thomas J. Use of cost-effectiveness analysis to compare the efficiency of study identification methods in systematic reviews. Systematic reviews. 2016;5(1):140.
15.    Miller HJ, Neupane R, Fayezizadeh M, Majumder A, Marks JM. POEM is a cost-effective procedure: cost-utility analysis of endoscopic and surgical treatment options in the management of achalasia. Surgical endoscopy. 2016.
16.    Zimovetz EA, Beard SM, Hodgkins P, Bischof M, Mauskopf JA, Setyawan J. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate. CNS drugs. 2016.
17.    Tolla MT, Norheim OF, Memirie ST, Abdisa SG, Ababulgu A, Jerene D, et al. Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis. Cost effectiveness and resource allocation : C/E. 2016;14:10.
18.    McFarland A. A cost utility analysis of the clinical algorithm for nasogastric tube placement confirmation in adult hospital patients. Journal of advanced nursing. 2016.
19.    Leung W, Kvizhinadze G, Nair N, Blakely T. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis. PLoS medicine. 2016;13(8):e1002067.
20.    Gimeno-Ballester V, Mar J, O'Leary A, Adams R, San Miguel R. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert review of gastroenterology & hepatology. 2016:1-9.
21.    Stawowczyk E, Kawalec P, Pilc A. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland. European journal of clinical pharmacology. 2016.
22.    Tapper EB, Hughes MS, Buti M, Dufour JF, Flamm S, Firdoos S, et al. The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Transplantation. 2016.
23.    Stawowczyk E, Kawalec P, Pilc A. Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland. PloS one. 2016;11(8):e0160444.
24.    Cheng Q, Lazzarini PA, Gibb M, Derhy PH, Kinnear EM, Burn E, et al. A cost-effectiveness analysis of optimal care for diabetic foot ulcers in Australia. International wound journal. 2016.
25.    van Keep M, Gairy K, Seshagiri D, Thilakarathne P, Lee D. Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma. BMC cancer. 2016;16:598.
26.    Khunti K, Gillies CL, Dallosso H, Brady EM, Gray LJ, Kilgallen G, et al. Assessment of response rates and yields for Two opportunistic Tools for Early detection of Non-diabetic hyperglycaemia and Diabetes (ATTEND). A randomised controlled trial and cost-effectiveness analysis. Diabetes research and clinical practice. 2016;118:12-20.
27.    Chen YE, Kao SS, Chung RH. Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan. PloS one. 2016;11(8):e0160599.
28.    Sabater E, Lopez-Guillermo A, Rueda A, Salar A, Oyaguez I, Collar JM. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain. Applied health economics and health policy. 2016;14(4):465-77.
29.    Buti M, Dominguez-Hernandez R, Oyaguez I, Casado MA. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis]. Gastroenterologia y hepatologia. 2016;39(7):449-57.
30.    Alfirevic Z, Keeney E, Dowswell T, Welton NJ, Medley N, Dias S, et al. Methods to induce labour: a systematic review, network meta-analysis and cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2016;123(9):1462-70.
31.    McIntosh E, Gray A, Daniels J, Gill S, Ives N, Jenkinson C, et al. Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trial. Movement disorders : official journal of the Movement Disorder Society. 2016;31(8):1173-82.
32.    Cheung MC, Prica A, Graczyk J, Buckstein R, Chan KK. Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis. Leukemia & lymphoma. 2016;57(8):1865-75.
33.    Wilkins E, Fisher M, Brogan AJ, Talbird SE, La EM. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial. HIV medicine. 2016;17(7):505-15.
34.    Bagcioglu M, Demir A, Sulhan H, Karadag MA, Uslu M, Tekdogan UY. Comparison of flexible ureteroscopy and micropercutaneous nephrolithotomy in terms of cost-effectiveness: analysis of 111 procedures. Urolithiasis. 2016;44(4):339-44.


July 2016

1.    Ament JD, Yang Z, Nunley P, Stone MB, Lee D, Kim KD. Cost Utility Analysis of the Cervical Artificial Disc vs Fusion for the Treatment of 2-Level Symptomatic Degenerative Disc Disease: 5-Year Follow-up. Neurosurgery. 2016;79(1):135-45.
2.    Babu MA. Commentary: Surgical Management of the Elderly With Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. Neurosurgery. 2016.
3.    Brenner MJ. What Cost-Utility Analysis Can Teach Us About Facial Deformity: Gambles, Trade-offs, and Willingness to Pay. JAMA facial plastic surgery. 2016;18(4):249-50.
4.    Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Digestive diseases and sciences. 2016;61(7):2108-17.
5.    Cromwell I, Regier DA, Peacock SJ, Poh CF. Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada. The oncologist. 2016.
6.    Cui M, Tu CC, Chen EZ, Wang XL, Tan SC, Chen C. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China. Advances in therapy. 2016.
7.    Elias I, Ortega-Joaquin N, de la Cueva P, Del Pozo LJ, Moreno-Ramirez D, Boada A, et al. Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain. Actas dermo-sifiliograficas. 2016;107(6):498-508.
8.    Fundament T, Eldridge PR, Green AL, Whone AL, Taylor RS, Williams AC, et al. Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis. PloS one. 2016;11(7):e0159340.
9.    Gancarczyk SM, Jang ES, Swart EP, Makhni EC, Kadiyala RK. Percutaneous Trigger Finger Release: A Cost-effectiveness Analysis. The Journal of the American Academy of Orthopaedic Surgeons. 2016;24(7):475-82.
10.    Green W, Taylor M. Cost-Effectiveness Analysis of d-Nav for People with Diabetes at High Risk of Neuropathic Foot Ulcers. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2016.
11.    Greuter MJ, Berkhof J, Fijneman RJ, Demirel E, Lew JB, Meijer GA, et al. The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis. The British journal of radiology. 2016;89(1063):20150910.
12.    Hankin-Wei A, Rein DB, Hernandez-Romieu A, Kennedy MJ, Bulkow L, Rosenberg E, et al. Cost-effectiveness analysis of catch-up hepatitis A vaccination among unvaccinated/partially-vaccinated children. Vaccine. 2016;34(35):4243-9.
13.    Hernandez L, Guo S, Kinter E, Fay M. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Journal of medical economics. 2016;19(7):684-95.
14.    Hofer F, Achelrod D, Stargardt T. Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany. Applied health economics and health policy. 2016.
15.    Kabeshova A, Ben Hariz S, Tsakeu E, Benamouzig R, Launois R. Cost-effectiveness analysis of rifaximin-alpha administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France. Therapeutic advances in gastroenterology. 2016;9(4):473-82.
16.    Kidholm K, Rasmussen MK, Andreasen JJ, Hansen J, Nielsen G, Spindler H, et al. Cost-Utility Analysis of a Cardiac Telerehabilitation Program: The Teledialog Project. Telemedicine journal and e-health : the official journal of the American Telemedicine Association. 2016;22(7):553-63.
17.    Kim H, Gill B, Beriwal S, Huq MS, Roberts MS, Smith KJ. Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases. International journal of radiation oncology, biology, physics. 2016;95(4):1175-83.
18.    Kuznik A, Habib AG, Munube D, Lamorde M. Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis. BMC health services research. 2016;16(1):304.
19.    Leal JR, Heitman SJ, Conly JM, Henderson EA, Manns BJ. Cost-Effectiveness Analysis of the Use of Probiotics for the Prevention of Clostridium difficile-Associated Diarrhea in a Provincial Healthcare System. Infection control and hospital epidemiology. 2016:1-8.
20.    Lee JK, Jo YH, Kang CN. Cost-effectiveness Analysis of Existing Pedicle Screws Reusing Technique in Extension Revision Operation for Adjacent Segmental Stenosis After Lumbar Posterolateral Fusion. Spine. 2016;41(13):E785-90.
21.    Liu CC, Rudmik L. A Cost-effectiveness Analysis of Early vs Late Tracheostomy. JAMA otolaryngology-- head & neck surgery. 2016.
22.    Lodhia P, Gui C, Chandrasekaran S, Suarez-Ahedo C, Dirschl DR, Domb BG. The Economic Impact of Acetabular Labral Tears: A Cost-effectiveness Analysis Comparing Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Patients Without Osteoarthritis. The American journal of sports medicine. 2016;44(7):1771-80.
23.    Matteucci F, Solinas L, Turri V, Donati C, D'Errico V, Moretti A, et al. IntegoTM Infusion System: cost effectiveness analysis focusing on dosimetry, sterility and management. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the So. 2016.
24.    Parker C, Woods B, Eaton J, Ma E, Selby R, Benson E, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. Journal of medical economics. 2016:1-33.
25.    Rajagopalan K, Trueman D, Crowe L, Squirrell D, Loebel A. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. PharmacoEconomics. 2016;34(7):709-21.
26.    Raykar N, Nigam A, Chisholm D. An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance. Cost effectiveness and resource allocation : C/E. 2016;14:9.
27.    Richard P, Phillips M, Smith W, Davidson D, Kim E, Kane G. Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy for Preoperative Treatment of Extremity Soft Tissue Sarcomas. International journal of radiation oncology, biology, physics. 2016;95(3):999-1008.
28.    Scangas GA, Remenschneider AK, Su BM, Shrime MG, Metson R. Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyposis. The Laryngoscope. 2016.
29.    Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, Ternouth A, Miravitlles M, Rutten-van Molken M, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat(R) fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Therapeutic advances in respiratory disease. 2016.
30.    Shrime MG, Verguet S, Johansson KA, Desalegn D, Jamison DT, Kruk ME. Task-sharing or public finance for the expansion of surgical access in rural Ethiopia: an extended cost-effectiveness analysis. Health policy and planning. 2016;31(6):706-16.
31.    Varghese L, Mungall B, Zhang XH, Hoet B. Response to Wu et al. - Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong. Human vaccines & immunotherapeutics. 2016:1-6.
32.    Vennera Mdel C, Valero A, Uria E, Forne C, Picado C. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain. Clinical drug investigation. 2016;36(7):567-78.
33.    Verguet S, Kim JJ, Jamison DT. Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. PharmacoEconomics. 2016.
34.    Verhoef TI, Trend V, Kelly B, Robinson N, Fox P, Morris S. Cost-effectiveness analysis of offering free leisure centre memberships to physically inactive members of the public receiving state benefits: a case study. BMC public health. 2016;16:616.
35.    Wallbillich JJ, Forde B, Havrilesky LJ, Cohn DE. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. Gynecologic oncology. 2016;142(1):144-9.
36.    Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, et al. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. Clinical lung cancer. 2016.
37.    Xu X, Ma YY, Zou HD. Cost-Utility Analysis of Cataract Surgery in Advanced Glaucoma Patients. Journal of glaucoma. 2016;25(7):e657-62.
38.    Zhang P, Wen F, Li Q. FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2016.
39.    Zhou J, Zhao R, Wen F, Zhang P, Tang R, Chen H, et al. Economic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial. Medicine. 2016;95(27):e3762.


June 2016

1.    Lanzeta I, Mar J, Arrospide A. Cost-utility analysis of an integrated care model for multimorbid patients based on a clinical trial. Gaceta sanitaria / SESPAS. 2016.
2.    Sjostrom S, Kopp Kallner H, Simeonova E, Madestam A, Gemzell-Danielsson K. Medical Abortion Provided by Nurse-Midwives or Physicians in a High Resource Setting: A Cost-Effectiveness Analysis. PloS one. 2016;11(6):e0158645.
3.    Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence. Patient preference and adherence. 2016;10:1025-35.
4.    Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis. Journal of medical genetics. 2016.
5.    Cromwell I, Gaudet M, Peacock SJ, Aquino-Parsons C. Cost-effectiveness analysis of anal cancer screening in women with cervical neoplasia in British Columbia, Canada. BMC health services research. 2016;16(1):206.
6.    Mercer SW, Fitzpatrick B, Guthrie B, Fenwick E, Grieve E, Lawson K, et al. The CARE Plus study - a whole-system intervention to improve quality of life of primary care patients with multimorbidity in areas of high socioeconomic deprivation: exploratory cluster randomised controlled trial and cost-utility analysis. BMC medicine. 2016;14(1):88.
7.    Taylor C, Thompson K, Finfer S, Higgins A, Jan S, Li Q, et al. Hydroxyethyl starch versus saline for resuscitation of patients in intensive care: long-term outcomes and cost-effectiveness analysis of a cohort from CHEST. The Lancet Respiratory medicine. 2016.
8.    Heard C, Chaboyer W, Anderson V, Gillespie BM, Whitty JA. Cost-effectiveness analysis alongside a pilot study of prophylactic negative pressure wound therapy. Journal of tissue viability. 2016.
9.    Hankin-Wei A, Rein DB, Hernandez-Romieu A, Kennedy MJ, Bulkow L, Rosenberg E, et al. Cost-effectiveness analysis of catch-up hepatitis A vaccination among unvaccinated/partially-vaccinated children. Vaccine. 2016.
10.    Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, et al. Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis. Drug safety. 2016.
11.    Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016.
12.    Chuang LH, Verheggen BG, Charokopou M, Gibson D, Grandy S, Kartman B. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. Journal of medical economics. 2016:1-8.
13.    Furlan JC, Craven BC, Fehlings MG. Surgical Management of the Elderly With Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. Neurosurgery. 2016.
14.    Uruena A, Vizzotti C, San Juan JA. Response to Orellano et al. regarding cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission. Vaccine. 2016;34(28):3222.
15.    Orellano PW, Salomon OD. Will dengue vaccination be cost-effective for Argentina? Reply to letter by Uruena et al. regarding "Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission". Vaccine. 2016;34(28):3221.
16.    Yun BJ, Myriam Hunink MG, Prabhakar AM, Heng M, Liu SW, Qudsi R, et al. Diagnostic Imaging Strategies for Occult Hip Fractures - A Decision and Cost-effectiveness Analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2016.
17.    Dilokthornsakul P, Chaiyakunapruk N, Campbell JD. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter? The Journal of asthma : official journal of the Association for the Care of Asthma. 2016:0.
18.    Williams C, Lewsey JD, Briggs AH, Mackay DF. Cost-Effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial. Medical decision making : an international journal of the Society for Medical Decision Making. 2016.
19.    Ke W, Zhang C, Liu L, Gao Y, Yao Z, Ye X, et al. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Hepatology international. 2016.
20.    Berrigan P, Bardouille T, MacLellan M, Mohamed IS, Murthy M. Cost-utility analysis of magnetoencephalography used to inform intracranial electrode placement in patients with drug resistant epilepsy: a model based analysis. Journal of evaluation in clinical practice. 2016.
21.    Pedersen K, Sorbye SW, Kristiansen IS, Burger EA. Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2016.
22.    Muduma G, Odeyemi I, Pollock RF. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. Journal of medical economics. 2016:1-8.
23.    Tuffaha HW, Roberts S, Chaboyer W, Gordon LG, Scuffham PA. Cost-effectiveness Analysis of Nutritional Support for the Prevention of Pressure Ulcers in High-Risk Hospitalized Patients. Advances in skin & wound care. 2016;29(6):261-7.
24.    Riesco-Martinez MC, Berry SR, Ko YJ, Mittmann N, Giotis A, Lien K, et al. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. Journal of oncology practice / American Society of Clinical Oncology. 2016;12(6):e710-23.
25.    Zhou J, Zhao R, Wen F, Zhang P, Wu Y, Tang R, et al. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials. Tumori. 2016;2016(3):294-300.
26.    Merry M, Boulware DR. Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;62(12):1564-8.
27.    Scangas GA, Su BM, Remenschneider AK, Shrime MG, Metson R. Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis. International forum of allergy & rhinology. 2016;6(6):582-9.
28.    O'Day K, Levy WC, Johnson M, Jacobson AF. Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA. Applied health economics and health policy. 2016;14(3):361-73.
29.    Ono Y, Osuga K, Takura T, Nakamura M, Shibamoto K, Yamamoto A, et al. Cost-Effectiveness Analysis of Percutaneous Sclerotherapy for Venous Malformations. Journal of vascular and interventional radiology : JVIR. 2016;27(6):831-7.
30.    Foteff C, Kennedy S, Milton AH, Deger M, Payk F, Sanderson G. Cost-Utility Analysis of Cochlear Implantation in Australian Adults. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2016;37(5):454-61.
31.    Morris S, Patel NV, Dobson J, Featherstone RL, Richards T, Luengo-Fernandez R, et al. Cost-utility analysis of stenting versus endarterectomy in the International Carotid Stenting Study. International journal of stroke : official journal of the International Stroke Society. 2016;11(4):446-53.
32.    Perez-Ruiz F, Diaz-Torne C, Carcedo D. Cost-effectiveness analysis of febuxostat in patients with gout in Spain. Journal of medical economics. 2016;19(6):604-10.
33.    Escolar-Albaladejo G, Baron-Esquivias G, Zamorano JL, Betegon-Nicolas L, Canal-Fontcuberta C, de Salas-Cansado M, et al. [Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain]. Atencion primaria / Sociedad Espanola de Medicina de Familia y Comunitaria. 2016;48(6):394-405.
34.    Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA. Cost-utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients. The Journal of asthma : official journal of the Association for the Care of Asthma. 2016;53(5):538-45.
35.    Larsen MH, Wahl AK, Krogstad AL, Aas E. Cost-utility Analysis of Supported Self-management with Motiva-tional Interviewing for Patients with Psoriasis. Acta dermato-venereologica. 2016;96(5):664-8.
36.    Berenguer J, Rivero A, Blasco AJ, Arribas JR, Boix V, Clotet B, et al. Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades infecciosas y microbiologia clinica. 2016;34(6):361-71.
37.    Hansson E, Ekman I, Swedberg K, Wolf A, Dudas K, Ehlers L, et al. Person-centred care for patients with chronic heart failure - a cost-utility analysis. European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology. 2016;15(4):276-84.
38.    van den Akker-van Marle ME, Moojen WA, Arts MP, Vleggeert-Lankamp CL, Peul WC. Interspinous process devices versus standard conventional surgical decompression for lumbar spinal stenosis: cost-utility analysis. The spine journal : official journal of the North American Spine Society. 2016;16(6):702-10.


May 2016
1.    Stomberg C, Albaugh M, Shiffman S, Sood N. A cost-effectiveness analysis of over-the-counter statins. The American journal of managed care. 2016;22(5):e294-303.
2.    de Sonneville-Koedoot C, Stolk E, Rietveld T, Franken MC. Response to "Putting the cart before the horse: A cost effectiveness analysis of treatments for stuttering in young children requires evidence that the treatments analyzed were effective". Journal of communication disorders. 2016.
3.    Gulliford MC, Charlton J, Booth HP, Fildes A, Khan O, Reddy M, et al. Health Services and Delivery Research.  Costs and outcomes of increasing access to bariatric surgery for obesity: cohort study and cost-effectiveness analysis using electronic health records. Southampton (UK): NIHR Journals Library
4.    Castelnuovo G, Pietrabissa G, Cattivelli R, Manzoni GM, Molinari E. Not Only Clinical Efficacy in Psychological Treatments: Clinical Psychology Must Promote Cost-Benefit, Cost-Effectiveness, and Cost-Utility Analysis. Frontiers in psychology. 2016;7:563.
5.    Phibbs CS, Love SR, Jacobson AK, Edson R, Su P, Uyeda L, et al. At-Home Versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). Journal of general internal medicine. 2016.
6.    Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M. COMPARING 2- AND 3-DOSE 9-VALENT HPV VACCINE SCHEDULES IN THE U.S.: A COST-EFFECTIVENESS ANALYSIS. The Journal of infectious diseases. 2016.
7.    Takura T, Tachibana K, Isshiki T, Sumitsuji S, Kuroda T, Mizote I, et al. Preliminary report on a cost-utility analysis of revascularization by percutaneous coronary intervention for ischemic heart disease. Cardiovascular intervention and therapeutics. 2016.
8.    Penaloza-Ramos MC, Jowett S, Barton P, Roalfe A, Fletcher K, Taylor CJ, et al. Cost-effectiveness analysis of different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack: Economic analysis of the PAST-BP study. European journal of preventive cardiology. 2016.
9.    Fukuda H, Moriwaki K. Cost-Effectiveness Analysis of Safety-Engineered Devices. Infection control and hospital epidemiology. 2016:1-10.
10.    Romanelli M, Gilligan AM, Waycaster CR, Dini V. Difficult-to-heal wounds of mixed arterial/venous and venous etiology: a cost-effectiveness analysis of extracellular matrix. ClinicoEconomics and outcomes research : CEOR. 2016;8:153-61.
11.    Canestaro WJ. Capsule Commentary on Phibbs et. al., At-Home versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). Journal of general internal medicine. 2016.
12.    Qureshi N, Weng S, Hex N. The role of cost-effectiveness analysis in the development of indicators to support incentive-based behaviour in primary care in England. Journal of health services research & policy. 2016.
13.    Gounder PP, Bulkow LR, Meltzer MI, Bruce MG, Hennessy TW, Snowball M, et al. Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983-2012. International journal of circumpolar health. 2016;75:31115.
14.    Nguyen TP, Wright EP, Nguyen TT, Schuiling-Veninga CC, Bijlsma MJ, Nguyen TB, et al. Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam. PloS one. 2016;11(5):e0155699.
15.    Lodhia P, Gui C, Chandrasekaran S, Suarez-Ahedo C, Dirschl DR, Domb BG. The Economic Impact of Acetabular Labral Tears: A Cost-effectiveness Analysis Comparing Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Patients Without Osteoarthritis. The American journal of sports medicine. 2016.
16.    Fusco F, Turchetti G. Telerehabilitation after total knee replacement in Italy: cost-effectiveness and cost-utility analysis of a mixed telerehabilitation-standard rehabilitation programme compared with usual care. BMJ open. 2016;6(5):e009964.
17.    Garcia A, Ortiz de Lejarazu R, Reina J, Callejo D, Cuervo J, Morano R. Cost-Effectiveness Analysis Of Quadrivalent Influenza Vaccine In Spain. Human vaccines & immunotherapeutics. 2016:0.
18.    Jiang M, You JH. Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome. Pharmacogenomics. 2016;17(7):701-13.
19.    Kjerstad E, Tuntland HK. Reablement in community-dwelling older adults: a cost-effectiveness analysis alongside a randomized controlled trial. Health economics review. 2015;6(1):15.
20.    Gasparini R, Landa P, Amicizia D, Icardi G, Ricciardi W, de Waure C, et al. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero(R)) against meningococcal B disease: A cost-effectiveness analysis. Human vaccines & immunotherapeutics. 2016:1-14.
21.    Granados-Garcia V, Contreras AM, Garcia-Pena C, Salinas-Escudero G, Thein HH, Flores YN. Cost-Effectiveness Analysis of Different Testing Strategies that Use Antibody Levels to Detect Chronic Hepatitis C in Blood Donors. PloS one. 2016;11(5):e0154625.
22.    Zheng HR, Wen F, Wu YF, Wheeler JR, Li Q. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective. European journal of cancer care. 2016.
23.    Elias I, Oyaguez I, Alvarez-Sala LA, Garcia-Bragado F, Navarro A, Gonzalez P, et al. Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2016;40(n03):187-208.
24.    Riesco-Martinez MC, Berry SR, Ko YJ, Mittmann N, Giotis A, Lien K, et al. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. Journal of oncology practice / American Society of Clinical Oncology. 2016;12(6):e710-23.
25.    Sohn M, Talbert J, Moga DC, Blumenschein K. A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy. Attention deficit and hyperactivity disorders. 2016.
26.    Vennera MD, Valero A, Uria E, Forne C, Picado C. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain. Clinical drug investigation. 2016.
27.    Haacker M, Fraser-Hurt N, Gorgens M. Effectiveness of and Financial Returns to Voluntary Medical Male Circumcision for HIV Prevention in South Africa: An Incremental Cost-Effectiveness Analysis. PLoS medicine. 2016;13(5):e1002012.
28.    Wallbillich JJ, Forde B, Havrilesky LJ, Cohn DE. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. Gynecologic oncology. 2016.
29.    Russell LB, Sinha A. Strengthening Cost-Effectiveness Analysis for Public Health Policy. American journal of preventive medicine. 2016;50(5 Suppl 1):S6-s12.
30.    Fragoulakis V, Mitropoulou C, van Schaik RH, Maniadakis N, Patrinos GP. An Alternative Methodological Approach for Cost-Effectiveness Analysis and Decision Making in Genomic Medicine. Omics : a journal of integrative biology. 2016;20(5):274-82.
31.    Okumura LM, Riveros BS, Gomes-da-Silva MM, Veroneze I. A cost-effectiveness analysis of two different antimicrobial stewardship programs. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2016;20(3):255-61.
32.    Luyten J, Naci H, Knapp M. Economic evaluation of mental health interventions: an introduction to cost-utility analysis. Evidence-based mental health. 2016;19(2):49-53.
33.    Stawowczyk E, Kawalec P, Pilc A. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland. Pharmacotherapy. 2016;36(5):472-81.
34.    Nwachukwu BU, Schairer WW, McCormick F, Dines DM, Craig EV, Gulotta LV. Arthroplasty for the surgical management of complex proximal humerus fractures in the elderly: a cost-utility analysis. Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons  [et al]. 2016;25(5):704-13.
35.    Marcellusi A, Viti R, Russo S, Andreoni M, Antinori A, Mennini FS. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective. Clinical drug investigation. 2016;36(5):377-87.
36.    Kapoor A, Shaffer N, Hanchate A, Roberts M, Smith K. Massachusetts Health Reform Cost Less and Was More Effective for Uninsured Individuals With Venous Thromboembolism: A Cost-Effectiveness Analysis. Medical care. 2016;54(5):474-82.
37.    Kawamoto Y, Mouri M, Taira T, Iseki H, Masamune K. Cost-Effectiveness Analysis of Deep Brain Stimulation in Patients with Parkinson's Disease in Japan. World neurosurgery. 2016;89:628-35.e1.
38.    Whalen J, Stillman I, Ambavane A, Felber E, Makenbaeva D, Bolinder B. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia. Journal of medical economics. 2016;19(5):445-61.
39.    Jain KM, Zulliger R, Maulsby C, Kim JJ, Charles V, Riordan M, et al. Cost-Utility Analysis of Three U.S. HIV Linkage and Re-engagement in Care Programs from Positive Charge. AIDS and behavior. 2016;20(5):973-6.
40.    Strand KB, Chisholm D, Fekadu A, Johansson KA. Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis. Health policy and planning. 2016;31(4):504-13.
41.    Zur RM, Zaric GS. A microsimulation cost-utility analysis of alcohol screening and brief intervention to reduce heavy alcohol consumption in Canada. Addiction (Abingdon, England). 2016;111(5):817-31.
42.    Frederix I, Hansen D, Coninx K, Vandervoort P, Vandijck D, Hens N, et al. Effect of comprehensive cardiac telerehabilitation on one-year cardiovascular rehospitalization rate, medical costs and quality of life: A cost-effectiveness analysis. European journal of preventive cardiology. 2016;23(7):674-82.
43.    Garcia-Ruiz AJ, Quintano Jimenez JA, Garcia-Agua Soler N, Ginel Mendoza L, Hidalgo Requena A, Del Moral F. [Quality of life of patients with asthma on beclomethasone/formoterol. Cost-utility analysis]. Semergen / Sociedad Espanola de Medicina Rural y Generalista. 2016;42(4):225-34.
44.    De Lossada A, Oteo-Alvaro A, Gimenez S, Oyaguez I, Rejas J. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective]. Semergen / Sociedad Espanola de Medicina Rural y Generalista. 2016;42(4):235-43.
45.    Pinol C. Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain. Neurologia (Barcelona, Spain). 2016;31(4):247-54.
46.    Takura T, Yoshimatsu M, Sugimori H, Takizawa K, Furumatsu Y, Ikeda H, et al. Cost-Effectiveness Analysis of Percutaneous Vertebroplasty for Osteoporotic Compression Fractures. Clinical spine surgery. 2016.